

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2021309779 B2**

(54) Title
EGFR inhibitor

(51) International Patent Classification(s)
A61K 31/519 (2006.01) **A61P 43/00** (2006.01)
A61P 35/00 (2006.01) **C07D 487/04** (2006.01)

(21) Application No: **2021309779** (22) Date of Filing: **2021.07.14**

(87) WIPO No: **WO22/014639**

(30) Priority Data

(31) Number	(32) Date	(33) Country
2020-121525	2020.07.15	JP

(43) Publication Date: **2022.01.20**

(44) Accepted Journal Date: **2024.06.27**

(71) Applicant(s)
Taiho Pharmaceutical Co., Ltd.

(72) Inventor(s)
OGUCHI Kei

(74) Agent / Attorney
PHILLIPS ORMONDE FITZPATRICK, PO Box 323, COLLINS STREET WEST, VIC, 8007, AU

(56) Related Art
WO 2020/145374 A1

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局

(43) 国際公開日
2022年1月20日(20.01.2022)



(10) 国際公開番号

WO 2022/014639 A1

(51) 国際特許分類:

A61K 31/519 (2006.01) A61P 43/00 (2006.01)
A61P 35/00 (2006.01) C07D 487/04 (2006.01)

(21) 国際出願番号: PCT/JP2021/026461

(22) 国際出願日: 2021年7月14日(14.07.2021)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:

特願 2020-121525 2020年7月15日(15.07.2020) JP

(71) 出願人: 大鵬薬品工業株式会社
(TAIHO PHARMACEUTICAL CO., LTD.) [JP/
JP]; 〒1018444 東京都千代田区神田錦町
1-2-7 Tokyo (JP).

(72) 発明者: 小口 憩 (OGUCHI Kei); 〒3002611 茨
城県つくば市大久保3 大鵬薬品工業
株式会社内 Ibaraki (JP).


(74) 代理人: 小林 浩, 外 (KOBAYASHI Hiroshi et
al.); 〒1040028 東京都中央区八重洲二丁目
8番7号 福岡ビル9階 阿部・井窪・
片山法律事務所 Tokyo (JP).

(81) 指定国(表示のない限り、全ての種類の国内保
護が可能): AE, AG, AL, AM, AO, AT, AU, AZ,
BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH,
CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ,
NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT,
QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL,
ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) 指定国(表示のない限り、全ての種類の広域保
護が可能): ARIPO (BW, GH, GM, KE, LR, LS,
MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM,
ZW), ユーラシア (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: EGFR INHIBITOR

(54) 発明の名称: E G F R阻害剤



[図1]



*: P<0.001

(57) Abstract: Provided is a therapeutic agent for diseases asso-
ciated with EGFR, the agent containing, as an active ingredient,
a compound having EGFR inhibitory activity and brain perme-
ability. The present invention is a compound represented by gen-
eral formula (I) [wherein R₁, R₂, R₃, R₄, and R₅ are as defined
in the specification] or a salt thereof, and a therapeutic agent for
diseases associated with EGFR, the agent containing, as an active
ingredient, a compound represented by general formula (I) or a
salt thereof.

(57) 要約: E G F R阻害活性を有し、かつ脳移行性を有
する化合物を有効成分として含有する、E G F Rが関与
する疾患の治療剤の提供。一般式 (I) [式中、R₁、
R₂、R₃、R₄及びR₅は明細書中で定義した通りの
意味を有する] で表される化合物又はその塩、並びに下
記一般式 (I) で表される化合物又はその塩を有効成分
として含有するE G F Rが関与する疾患の治療剤。

TM), ヨーロッパ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

添付公開書類：

- 国際調査報告（条約第21条(3)）
- 明細書の別個の部分として表した配列リスト（規則5.2(a)）

DESCRIPTION

Title of Invention: EGFR INHIBITOR

Technical Field

[0001]

The present invention relates to an EGFR inhibitor containing a pyrimidine compound or a salt thereof.

Background Art

[0002]

EGFR (which is also referred to as "ErbB1") is receptor tyrosine kinase belonging to the ErbB family and has been reported to contribute to cell growth or apoptosis inhibition by binding to epidermal growth factor (which is also referred to as "EGF"), mainly in epithelial tissues, among normal tissues (Non Patent Literature 1).

[0003]

EGFR is considered to be a proto-oncogene. It has been reported that EGFR gene amplification, overexpression, mutation and the like occur in various types of cancers. From non-clinical and clinical research data, it is considered that activation of EGFR and downstream signals play an important role in the survival and/or proliferation, etc. of cancer cells associated with the genetic abnormality, overexpression and the like of EGFR. For example, a mutation in exon 19 region of EGFR, which deletes amino acids at positions 746 to 750 (which is also referred to as "exon 19 deletion mutation"), and a mutation in exon 21 region, which substitutes an amino acid leucine at position 858 with arginine (which is also referred to as "L858R mutation") are considered to contribute to the survival and/or proliferation of

cancer cells by autophosphorylating EGFR in an EGF-independent manner and thereby inducing kinase activity (Non Patent Literature 2). It has been reported that these mutations are present in approximately 30 to 50% of non-small cell lung cancer cases in East Asia and approximately 10% of non-small cell lung cancer cases in Europe and the United States (Non Patent Literature 3).

[0004]

Accordingly, an inhibitor capable of regulating the kinase activity of EGFR is assumed to inhibit EGFR and downstream signals in cancer cells having EGFR gene amplification, overexpression and/or mutation, so as to exhibit antitumor effects on the cancer cells. Therefore, such an inhibitor is considered to be useful for the treatment, life-prolonging, or QOL improvement of cancer patients.

[0005]

Hence, a plurality of EGFR inhibitors have heretofore been researched and developed as anticancer agents and are used in the treatment of EGFR mutation-positive tumor. For example, drugs such as afatinib, gefitinib, and erlotinib have been approved as therapeutic agents for EGFR mutation-positive lung cancer having exon 19 deletion mutation or L858R mutation. Also, osimertinib has been approved as a therapeutic agent for EGFR mutation-positive lung cancer having exon 19 deletion mutation or L858R mutation as well as a mutation in exon 20 region, which substitutes an amino acid threonine at position 790 with methionine (which is also referred to as "T790M mutation").

[0006]

A mutation in exon 20 region, which insets one or more amino acids (which is also referred to as "exon 20 insertion mutation") is also considered as an activating mutation in lung cancer and the like (Non Patent Literature 4). It has been reported that cancer having such a mutation tends to be low sensitive to a plurality of existing EGFR inhibitors. For example, as for the clinical effect of afatinib on EGFR

mutation-positive lung cancer, it has been reported that its effect on exon 20 insertion mutation tends to be much lower than that on exon 19 deletion mutation or L858R mutation (Non Patent Literature 5). Regarding lung cancer having exon 20 insertion mutation of EGFR, multiple clinical trials have been carried out. However, under the current circumstances, a therapeutic method therefor has not yet been established. Therefore, it has been desired to develop an EGFR inhibitor having inhibitory activity against exon 20 insertion mutation.

[0007]

It has been reported that brain metastasis occurs in approximately 25% to 40% of lung cancer cases, in approximately 15% to 30% of breast cancer cases, and in certain percentages of other multiple cancer cases (Non Patent Literatures 6 and 7).

[0008]

From the viewpoint of the control of pathological conditions including brain metastasis nidus, it has been desired to develop an EGFR inhibitor having inhibitory activity against EGFR mutations and also having brain penetration properties.

[0008a]

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

[0008b]

Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group thereof.

Citation List

Non Patent Literature

[0009]

[Non Patent Literature 1] Nat. Rev. Cancer, vol. 6, pp. 803-812 (2006)

[Non Patent Literature 2] Nature Medicine, vol. 19, pp. 1389-1400 (2013)

[Non Patent Literature 3] Nat. Rev. Cancer, vol. 7, pp. 169-181 (2007)

[Non Patent Literature 4] Signal Transduct Target Ther. 4: 5, pp. 1-10 (2019)

[Non Patent Literature 5] Lancet Oncol. vol. 16, pp. 830-838 (2015)

[Non Patent Literature 6] Current Oncology, 25, p. S103-S114 (2018)

[Non Patent Literature 7] Breast Cancer Research, 18 (1), 8, p. 1-9 (2016)

Summary of Invention

[0010]

An aspect of the present invention is to provide a therapeutic agent for a disease associated with EGFR, comprising a compound that has EGFR inhibitory activity and has brain penetration properties as an active ingredient.


[0011]

As a result of intensive studies, the present inventors have found that a compound represented by the following formula (I) having pyrimidine as a basic skeleton, or a salt thereof has EGFR inhibitory activity and brain penetration properties and is useful as a therapeutic agent for diseases associated with EGFR (particularly, malignant tumor) by inhibiting EGFR, reaching the completion of the present invention.

[0012]

Specifically, one embodiment of the present invention includes the following:

[1] A therapeutic agent for a disease associated with EGFR, comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;


R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[2] The therapeutic agent according to [1], wherein the pyrimidine compound is a compound represented by the following formula (II):



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[3] The therapeutic agent according to [1] or [2], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₂ is a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups as a substituent(s).

[4] The therapeutic agent according to any of [1] to [3], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₃ is a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s).

[5] The therapeutic agent according to any of [1] to [4], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₅ is a phenyl group optionally having 1 or 2 substituents selected from the group consisting of fluorine atoms and chlorine atoms.

[6] The therapeutic agent according to any of [1] to [5], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₁ is a methyl group, a tert-butyl group, or a cyclopropyl group.

[7] The therapeutic agent according to any of [1] to [6], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₂ is a methyl group, an ethyl group, a methoxymethyl group, or an ethoxymethyl group.

[8] The therapeutic agent according to any of [1] to [7], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₃ is a methyl group.

[9] The therapeutic agent according to any of [1] to [8], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₄ is a hydrogen atom.

[10] The therapeutic agent according to any of [1] to [9], wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₅ is a phenyl group.

[11] The therapeutic agent according to any of [1] to [10], wherein the pyrimidine compound is a compound selected from the following (1) to (3):

(1) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,


(2) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, and

(3) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3,3-dimethylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[12] The therapeutic agent according to any of [1] to [11], wherein the pyrimidine compound is 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[13] The therapeutic agent according to any of [1] to [12], wherein the disease associated with EGFR is malignant tumor having EGFR overexpression, EGFR gene amplification, or an EGFR mutation.

[14] An EGFR inhibitor comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;


R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[15] A therapeutic agent for EGFR-positive tumor, comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;


R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[16] A pharmaceutical composition for use in the treatment of a disease associated with EGFR, the pharmaceutical composition comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[17] The pharmaceutical composition according to [16], wherein the disease associated with EGFR is malignant tumor having EGFR overexpression, EGFR gene amplification, or an EGFR mutation.

[0013]

The present invention also relates to the following aspects:

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating a disease associated with EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating a disease associated with EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for a disease associated with EGFR.

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating EGFR-positive tumor.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating EGFR-positive tumor.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for EGFR-positive tumor.

A method for treating a disease associated with EGFR, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A method for treating EGFR-positive tumor, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 18 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 18 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for malignant tumor having exon 18 mutant EGFR.

A method for treating malignant tumor having exon 18 mutant EGFR, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 19 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 19 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for malignant tumor having exon 19 mutant EGFR.

A method for treating malignant tumor having exon 19 mutant EGFR, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 20 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 20 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for malignant tumor having exon 20 mutant EGFR.

A method for treating malignant tumor having exon 20 mutant EGFR, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 21 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor having exon 21 mutant EGFR.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for malignant tumor having exon 21 mutant EGFR.

A method for treating malignant tumor having exon 21 mutant EGFR, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor resistant to an existing EGFR inhibitor.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for treating malignant tumor resistant to an existing EGFR inhibitor.

Use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for producing a therapeutic agent for malignant tumor resistant to an existing EGFR inhibitor.

A method for treating malignant tumor resistant to an existing EGFR inhibitor, comprising administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

Advantageous Effects of Invention

[0014]

The therapeutic agent for a disease associated with EGFR according to the present invention provides a novel therapeutic method for treating a disease associated with EGFR, or EGFR-positive tumor.

The compound of the present invention or a salt thereof has excellent inhibitory activity against wild-type EGFR and mutant EGFR and has excellent brain penetration properties, antitumor effect on malignant tumor, and effect of extending a survival period.

Brief Description of Drawings

[0015]

[Figure 1] Figure 1 shows the antitumor effects of compounds of Example 2, 11 and 12 against models involving subcutaneous transplantation of the H1975-EGFRinsSVD cell line.

[Figure 2] Figure 2 shows the body weight change percentage of mice when the compounds of Examples 2, 11 and 12 were administered to the models involving subcutaneous transplantation of the H1975-EGFRinsSVD cell line.


[Figure 3] Figure 3 shows the antitumor effects of the compound of Example 11 against models involving direct brain transplantation of the Luciferase gene-introduced exon 20 insertion mutant EGFR expressing cell line (H1975-EGFRinsSVD-Luc).

[Figure 4] Figure 4 shows the survival rate of mice when the compound of Example 11 was administered to the models involving direct brain transplantation of the Luciferase gene-introduced exon 20 insertion mutant EGFR expressing cell line (H1975-EGFRinsSVD-Luc).

Description of Embodiments

[0016]


One embodiment of the present invention relates to a compound represented by the following formula (I), or a salt thereof:



(wherein R₁ to R₅ represents as defined above.)

[0017]

One preferred embodiment of the present invention is a pyrimidine compound represented by the following formula (II), or a salt thereof:



(wherein R₁ to R₅ represents as defined above.)

[0018]

The compound represented by the above formula (I) or formula (II) of the present invention is a compound having pyrrolo[2,3-d]pyrimidine as a basic structure, and this is a novel compound described in none of the aforementioned prior art publications, etc.

[0019]

In the present description, specific examples of the "halogen atom" may include a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom. Among these, a chlorine atom and a fluorine atom are preferable, and a fluorine atom is more preferable.

[0020]

In the present description, the "alkyl group" means a linear or branched saturated hydrocarbon group. Specific examples of the alkyl group may include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, and a hexyl group. Among these, a linear or branched alkyl group containing 1 to 4 carbon atoms is preferable, and a methyl group and a tert-butyl group are more preferable.

[0021]

In the present description, the "haloalkyl group" means a linear or branched saturated hydrocarbon group, in which one to all hydrogen atoms are substituted with the above-described halogen atoms. Specific examples of the haloalkyl group may include a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, a 1,1-difluoroethyl group, a 1,2-difluoroethyl group, a 2,2-difluoroethyl group, a 2,2,2-trifluoroethyl group, a monochloromethyl group, a dichloromethyl group, a trichloromethyl group, a 1-chloroethyl group, a 2-chloroethyl group, and a 1,1-dichloroethyl group. Among these, a linear or branched saturated hydrocarbon group containing 1 to 6 carbon atoms, in which 1 to 3 hydrogen atoms are substituted with the above-described halogen atoms, is preferable, and a monofluoromethyl group is more preferable.

[0022]

In the present description, the "cycloalkyl group" means a monocyclic or polycyclic saturated hydrocarbon group containing 3 to 7 carbon atoms. Specific

examples of the cycloalkyl group may include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. Among these, a cyclopropyl group and a cyclobutyl group are preferable.

[0023]

In the present description, the "aromatic hydrocarbon group" means a cyclic substituent consisting of carbon and hydrogen, having an unsaturated bond, in which $4e + 2$ (wherein e represents an integer of 1 or greater) electrons are contained in the cyclic π electron system.

[0024]

In the present description, the "C6-C14 aromatic hydrocarbon group" means a monocyclic or polycyclic aromatic hydrocarbon group containing 6 to 14 carbon atoms. Specific examples of the C6-C14 aromatic hydrocarbon group may include a phenyl group, a naphthyl group, a tetrahydronaphthyl group, and an anthracenyl group. Among these, a phenyl group is preferable.

[0025]

In the present description, the "aralkyl group" means the above-described alkyl group substituted with the above-described aromatic hydrocarbon group. Specific examples of the aralkyl group may include C7-C16 aralkyl groups such as a benzyl group, a phenylethyl group, a phenylpropyl group, a naphthylmethyl group, and a naphthylethyl group. Among these, a benzyl group is preferable.

[0026]

In the present description, the "unsaturated hydrocarbon group" means a linear or branched hydrocarbon group containing 2 to 6 carbon atoms, which comprises at least one carbon-carbon double bond or triple bond. Specific examples of the unsaturated hydrocarbon group may include a vinyl group, an allyl group, a methylvinyl group, a propenyl group, a butenyl group, a pentenyl group, a

hexenyl group, an ethynyl group, and a 2-propynyl group. Among these, a vinyl group, an allyl group, and a 1-propenyl group are preferable.

[0027]

In the present description, the "alkenyl group" means a linear or branched hydrocarbon group containing 2 to 6 carbon atoms, which comprises at least one carbon-carbon double bond. Specific examples of the alkenyl group may include C2-C6 alkenyl groups, such as a vinyl group, an allyl group, a 2-methyl-2-propenyl group, an isopropenyl group, a 1-, 2- or 3-butenyl group, a 2-, 3- or 4-pentenyl group, a 2-methyl-2-butenyl group, a 3-methyl-2-butenyl group, and a 5-hexenyl group. Among these, a vinyl group, an allyl group, a 1-propenyl group, and a 2-methyl-2-propenyl group are preferable.

[0028]

In the present description, the "alkynyl group" means a linear or branched unsaturated hydrocarbon group having at least one triple bond (for example, 1 or 2, and preferably 1 triple bond). Specific examples of the alkynyl group may include C2-C6 alkynyl groups such as an ethynyl group, a 1- or 2-propynyl group, a 1-, 2- or 3-butylnyl group, and a 1-methyl-2-propynyl group. Among these, an ethynyl group and a 2-propynyl group are preferable.

[0029]

In the present description, the "C3-C10 cyclic unsaturated hydrocarbon group" means a monocyclic or polycyclic hydrocarbon group containing 3 to 10 carbon atoms, which comprises at least one carbon-carbon double bond. Specific examples of the C3-C10 cyclic unsaturated hydrocarbon group may include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, and a cyclononyl group. Among these, a monocyclic or polycyclic hydrocarbon group containing 3 to 7

carbon atoms, which comprises at least one carbon-carbon double bond, is preferable, and a cyclopropenyl group is more preferable.

[0030]

In the present description, the "alkoxy group" means an oxy group having the above-described alkyl group. Specific examples of the alkoxy group may include C1-C6 alkoxy groups such as a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxy group, an isopentyloxy group, and a hexyloxy group. Among these, a methoxy group and an ethoxy group are preferable, and a methoxy group is more preferable.

[0031]

In the present description, the "haloalkoxy group" may include the above-described alkoxy group having at least one halogen atom (preferably 1 to 13, and more preferably 1 to 3 halogen atoms). Specific examples of the haloalkoxy group may include C1-C6 haloalkoxy groups such as a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a trichloromethoxy group, a fluoroethoxy group, a 1,1,1-trifluoroethoxy group, a monofluoro-n-propoxy group, a perfluoro-n-propoxy group, and a perfluoro-isopropoxy group.

[0032]

In the present description, the "cycloalkoxy group" means an oxy group having the above-described cycloalkyl group. Specific examples of the cycloalkoxy group may include C3-C7 cycloalkoxy groups such as a cyclopropoxy group, a cyclobutoxy group, a cyclopentyloxy group, a cyclohexyloxy group, and a cycloheptyloxy group. Among these, a cyclobutoxy group, a cyclopentyloxy group, and a cyclohexyloxy group are preferable.

[0033]

In the present description, the "aralkyloxy group" means an oxy group having the above-described aralkyl group. Specific examples of the aralkyloxy group may include C7-C20 aralkyloxy groups such as a benzyloxy group, a phenethyloxy group, a naphthylmethyloxy group, and a fluorenylmethyloxy group. Among these, a benzyloxy group is preferable.

[0034]

In the present description, the "alkylthio group" means a thioxy group having the above-described alkyl group. Specific examples of the alkylthio group may include C1-C6 alkylthio groups such as a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a tert-butylthio group, an n-pentylthio group, an isopentylthio group, and a hexylthio group. Among these, a methylthio group, an ethylthio group, and an n-propylthio group are preferable.

[0035]

In the present description, the "alkoxyalkyl group" means the above-described alkyl group having at least one of the above-described alkoxy groups. Specific examples of the alkoxyalkyl group may include C1-C6 alkoxy-C1-C6 alkyl groups such as a methoxymethyl group, an ethoxyethyl group, a methoxyethyl group, and a methoxypropyl group.

[0036]

In the present description, the "alkylamino group" means an amino group in which 1 or 2 hydrogen atoms are substituted with a linear or branched hydrocarbon group(s) containing 1 to 6 carbon atoms. Specific examples of the alkylamino group may include a methylamino group, an ethylamino group, a dimethylamino group, a diethylamino group, and an ethylmethylamino group. Among these, preferable is an amino group in which 1 or 2 hydrogen atoms are substituted with a linear or branched hydrocarbon group containing 1 to 3 carbon atoms.

[0037]

In the present description, the "monoalkylamino group" means an amino group in which one hydrogen atom is substituted with a linear or branched hydrocarbon group. Specific examples of the monoalkylamino group may include a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, an n-butylamino group, an isobutylamino group, a sec-butylamino group, a tert-butylamino group, a pentylamino group, and a hexylamino group. Among these, preferable is an amino group in which one hydrogen atom is substituted with a linear or branched hydrocarbon group containing 1 to 3 carbon atoms.

[0038]

In the present description, the "dialkylamino group" means an amino group in which two hydrogen atoms are substituted with linear or branched hydrocarbon groups containing 1 to 6 carbon atoms. Specific examples of the dialkylamino group may include a dimethylamino group, a diethylamino group, and an ethylmethylamino group. Among these, an amino group in which two hydrogen atoms are substituted with linear or branched hydrocarbon groups containing 1 to 3 carbon atoms is preferable, and a dimethylamino group is more preferable.

[0039]

In the present description, the "acyl group" means a formyl group in which a hydrogen atom is substituted with a linear or branched hydrocarbon group. Specific examples of the acyl group may include an acetyl group, an n-propanoyl group, an isopropanoyl group, an n-butyloyl group, and a tert-butyloyl group. Among these, a formyl group in which a hydrogen atom is substituted with a linear or branched hydrocarbon group containing 1 to 3 carbon atoms is preferable, and an acetyl group is more preferable.

[0040]

In the present description, the "acyloxy group" means an oxy group having the above-described acyl group. Specific examples of the acyloxy group may include an alkylcarbonyloxy group and an arylcarbonyloxy group. Among these, an oxy group in which a hydrogen atom of formyl group is substituted with a linear or branched hydrocarbon group containing 1 to 3 carbon atoms is preferable, and an alkylcarbonyloxy group is more preferable.

[0041]

In the present description, the "alkoxycarbonyl group" means a carbonyl group having the above-described alkoxy group. Specific examples of the alkoxycarbonyl group may include (C1-C6alkoxy)carbonyl groups such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group, a tert-butoxycarbonyl group, a pentyloxycarbonyl group, an isopentyloxycarbonyl group, and a hexyloxycarbonyl group. Among these, a tert-butoxycarbonyl group is preferable.

[0042]

In the present description, the "aralkyloxycarbonyl group" means a carbonyl group having the above-described aralkyloxy. Specific examples of the aralkyloxycarbonyl group may include (C6-C20 aralkyl)oxycarbonyl groups such as a benzyloxycarbonyl group, a phenethyloxycarbonyl group, a naphthylmethyloxycarbonyl group, and a fluorenylmethyloxycarbonyl group. Among these, a benzyloxycarbonyl group is preferable.

[0043]

In the present description, the "saturated heterocyclic group" means a monocyclic or polycyclic saturated heterocyclic group having at least one heteroatom (preferably 1 to 5, and more preferably 1 to 3 heteroatoms) selected from nitrogen atoms, oxygen atoms, and sulfur atoms. Specific examples of the saturated

heterocyclic group may include an aziridinyl group, an azetidiny group, an imidazolidinyl group, a morpholino group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a tetrahydrothiophenyl group, a thiazolidinyl group, and an oxazolidinyl group. Among these, an azetidiny group, a pyrrolidinyl group, and a piperidinyl group are preferable, and an azetidiny group and a pyrrolidinyl group are more preferable.

[0044]

In the present description, the "unsaturated heterocyclic group" means a monocyclic or polycyclic completely unsaturated or partially unsaturated heterocyclic group having at least one heteroatom (preferably 1 to 5, and more preferably 1 to 3 heteroatoms) selected from nitrogen atoms, oxygen atoms, and sulfur atoms. Specific examples of the unsaturated heterocyclic group may include an imidazolyl group, a thienyl group, a pyrrolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, an oxadiazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a pyridyl group, a pyrazyl group, a pyrimidinyl group, a pyridazinyl group, an indolyl group, an isoindolyl group, an indazolyl group, a triazolopyridyl group, a benzimidazolyl group, a benzoxazolyl group, a benzothiazolyl group, a benzothieryl group, a furanyl group, a benzofuranyl group, a purinyl group, a quinolyl group, an isoquinolyl group, a quinazolinyl group, a quinoxalyl group, a methylenedioxyphenyl group, an ethylenedioxyphenyl group, and a dihydrobenzofuranyl group. Among these, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isoxazolyl group, and a furanyl group are preferable; an imidazolyl group, a pyrazolyl group, and a thiazolyl group are more preferable; and an imidazolyl group is most preferable.

[0045]

In the present description, the "saturated heterocyclic oxy group" means an oxy group having the above-described saturated heterocyclic group. Specific

examples of the saturated heterocyclic oxy group may include a morpholinyl group, a 1-pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a 4-methyl-1-piperazinyl group, a tetrahydrofuran group, a tetrahydropyran group, a tetrahydrothiophenyl group, a thiazolidinyl group, and an oxazolidinyl group. Among these, a 1-pyrrolidinyl group, a piperidinyl group, and a piperazinyl group are preferable.

[0046]

In the compound represented by the formula (I) or the formula (II) of the present invention, R₁ is a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group.

[0047]

The "C1-C4 alkoxy group" in the "C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent" represented by R₁ is preferably a methoxy group or an ethoxy group, and most preferably a methoxy group. Herein, the number of substituents is preferably 1 to 3, and most preferably 1. When the C1-C4 alkyl group has two or more substituents, the substituents may be identical to or different from each other.

[0048]

The "C1-C4 alkyl group" in the "C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent" represented by R₁ is preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group, more preferably a methyl group, an ethyl group, an isopropyl group, or a tert-butyl group, and most preferably a methyl group or a tert-butyl group.

[0049]

The "C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent" represented by R₁ is preferably a C1-C4 alkyl group having 1 to 3 methoxy groups as substituents, more preferably a methyl group, an ethyl group, an

isopropyl group, a tert-butyl group, or a 1-methyl-1-methoxyethyl group, and most preferably a methyl group or a tert-butyl group.

[0050]

The "C3-C4 cycloalkyl group" represented by R₁ is preferably a cyclopropyl group or a cyclobutyl group, and most preferably a cyclopropyl group.

[0051]

R₁ is preferably a C1-C4 alkyl group optionally having 1 to 3 C1-C4 alkoxy groups as substituents, or a C3-C4 cycloalkyl group.

[0052]

R₁ is more preferably a C1-C4 alkyl group optionally having 1 to 3 methoxy groups as substituents, or a C3-C4 cycloalkyl group.

[0053]

R₁ is further preferably a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, a 1-methyl-1-methoxyethyl group, or a cyclopropyl group.

[0054]

R₁ is most preferably a methyl group, a tert-butyl group, or a cyclopropyl group.

[0055]

In the compound represented by the formula (I) or the formula (II) of the present invention, R₂ is a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group.

[0056]

The "halogen atom" represented by R₂ is preferably a fluorine atom or a chlorine atom.

[0057]

The "C1-C4 alkoxy group" in the "C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s)" represented by R₂ is preferably a methoxy group or an ethoxy group, and most preferably a methoxy group.

[0058]

The "C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s)" represented by R₂ is preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group, and most preferably a methyl group.

[0059]

The "C1-C6 alkyl group" in the "C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s)" represented by R₂ is preferably a C1-C6 alkyl group optionally having 1 to 5 methoxy groups, ethoxy groups, or fluorine atoms as a substituent(s) (specifically, a methyl group, a methoxymethyl group, an ethoxymethyl group, a methoxyethyl group, an ethoxyethyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, etc.), more preferably a C1-C6 alkyl group, further preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group, and most preferably a methyl group.

[0060]

The "C1-C6 alkoxy group" represented by R₂ is preferably a methoxy group or an ethoxy group, and most preferably a methoxy group.

[0061]

R₂ is preferably a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s). In one embodiment, R₂ is a C1-C6 alkyl group optionally having 1 to 5 methoxy groups, ethoxy groups, or fluorine atoms as a substituent(s). In another embodiment, R₂ is a methyl group, an ethyl

group, an n-propyl group, an isopropyl group, or a tert-butyl group (preferably a methyl group or an ethyl group, and more preferably a methyl group), each optionally having 1 to 5 methoxy groups, ethoxy groups, or fluorine atoms as a substituent(s).

[0062]

R₂ is more preferably a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups as a substituent(s). In one embodiment, R₂ is a C1-C6 alkyl group optionally having 1 to 5 methoxy groups or ethoxy groups as a substituent(s). In another embodiment, R₂ is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group (preferably a methyl group or an ethyl group, and more preferably a methyl group) each optionally having 1 to 5 methoxy groups or ethoxy groups as a substituent(s). In a further embodiment, R₂ is a methyl group, an ethyl group, a methoxymethyl group, or an ethoxymethyl group.

[0063]

R₂ is even more preferably a C1-C6 alkyl group.

[0064]

R₂ is further preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group.

R₂ is particularly preferably a methyl group or an ethyl group.

R₂ is most preferably a methyl group.

[0065]

In the compound represented by the formula (I) or the formula (II) of the present invention, R₃ is a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s).

[0066]

The "C1-C4 alkyl group" in the "C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s)" represented by R₃ is preferably a methyl group, an

ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group, more preferably a methyl group or an ethyl group, and most preferably a methyl group.

[0067]

The "C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s)" represented by R_3 is preferably a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, or an ethyl group, more preferably a methyl group, a trifluoromethyl group, or an ethyl group, and most preferably a methyl group.

[0068]

R_3 is preferably a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s).

[0069]

R_3 is more preferably a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, an ethyl group, a fluoroethyl group, a difluoroethyl group, a trifluoroethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group.

[0070]

R_3 is even more preferably a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, or an ethyl group.

[0071]

R_3 is further preferably a methyl group, a trifluoromethyl group, or an ethyl group.

R_3 is particularly preferably a methyl group or an ethyl group.

R_3 is most preferably a methyl group.

[0072]

In the compound represented by the formula (I) or the formula (II) of the present invention, R_4 is a hydrogen atom or a C1-C4 alkyl group.

[0073]

The "C1-C4 alkyl group" represented by R₄ is preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group, more preferably a methyl group or an ethyl group, and most preferably a methyl group.

[0074]

R₄ is preferably a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group.

[0075]

R₄ is more preferably a hydrogen atom, a methyl group, or an ethyl group.

[0076]

R₄ is further preferably a hydrogen atom or a methyl group.

R₄ is most preferably a hydrogen atom.

[0077]

In the compound represented by the formula (I) or the formula (II) of the present invention, R₅ is a phenyl group optionally having 1 to 3 substituents selected from the group consisting of fluorine atoms and chlorine atoms.

[0078]

R₅ is preferably a phenyl group optionally having 1 or 2 substituents selected from the group consisting of fluorine atoms and chlorine atoms.

[0079]

R₅ is more preferably a phenyl group, a 2-fluorophenyl group, a 3-chlorophenyl group, a 2,3-difluorophenyl group, a 2,4-difluorophenyl group, or a 3,5-difluorophenyl group.

[0080]

R₅ is most preferably a phenyl group.

[0081]

The compound of the present invention is preferably the compound represented by the formula (I) or the formula (II), or a salt thereof, wherein, in the formula (I) or the formula (II),

R₁ is a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group,

R₂ is a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups as a substituent(s),

R₃ is a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s),

R₄ is a hydrogen atom or a C1-C4 alkyl group, and

R₅ is a phenyl group optionally having 1 or 2 substituents selected from the group consisting of fluorine atoms and chlorine atoms.

[0082]

The compound of the present invention is more preferably the compound represented by the formula (I) or the formula (II), or a salt thereof, wherein, in the formula (I) or the formula (II),

R₁ is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, a 1-methyl-1-methoxyethyl group, a cyclopropyl group, or a cyclobutyl group,

R₂ is a methyl group, an ethyl group, an n-propyl group, a tert-butyl group, a methoxymethyl group, or an ethoxymethyl group,

R₃ is a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, an ethyl group, a fluoroethyl group, a difluoroethyl group, a trifluoroethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group,

R₄ is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a tert-butyl group, and

R₅ is a phenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 2,4-difluorophenyl group, a 2,3-difluorophenyl group, a 3,5-difluorophenyl group, a 2-chlorophenyl group, a 3-chlorophenyl group, a 2,4-dichlorophenyl group, or a 3,5-dichlorophenyl group.

[0083]

The compound of the present invention is even more preferably the compound represented by the formula (II), or a salt thereof, wherein, in the formula (II),

R₁ is a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, a 1-methyl-1-methoxyethyl group, or a cyclopropyl group,

R₂ is a methyl group, an ethyl group, a methoxymethyl group, or an ethoxymethyl group,

R₃ is a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, or an ethyl group,

R₄ is a hydrogen atom, a methyl group, or an ethyl group, and

R₅ is a phenyl group, a 2-fluorophenyl group, a 3-chlorophenyl group, a 2,3-difluorophenyl group, a 2,4-difluorophenyl group, or a 3,5-difluorophenyl group.

[0084]

The compound of the present invention is further preferably the compound represented by the formula (II), or a salt thereof, wherein, in the formula (II),

R₁ is a methyl group, a tert-butyl group, or a cyclopropyl group,

R₂ is a methyl group, an ethyl group, a methoxymethyl group, or an ethoxymethyl group,

R₃ is a methyl group, a trifluoromethyl group, or an ethyl group,

R₄ is a hydrogen atom or a methyl group, and

R₅ is a phenyl group.

[0085]

The compound of the present invention is further preferably the compound represented by the formula (II), or a salt thereof, wherein, in the formula (II),

R₁ is a methyl group, a tert-butyl group, or a cyclopropyl group,

R₂ is a methyl group, an ethyl group, or a methoxymethyl group,

R₃ is a methyl group,

R₄ is a hydrogen atom, and

R₅ is a phenyl group.

[0086]

The compound of the present invention is particularly preferably the compound represented by the formula (II), or a salt thereof, wherein, in the formula (II),

R₁ is a methyl group, a tert-butyl group, or a cyclopropyl group,

R₂ is a methyl group,

R₃ is a methyl group,

R₄ is a hydrogen atom, and

R₅ is a phenyl group.

[0087]

Specific examples of the compound represented by the formula (I) or the formula (II) may include compounds produced in the following Examples, but are not limited thereto.

[0088]

One embodiment of the present invention relates to a compound selected from the following (1) to (18), or a salt thereof. One embodiment of the present invention relates to a compound selected from the following (1) to (15), or a salt thereof.

(1) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

- (2) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (3) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3,3-dimethylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (4) 7-(R)-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-(3,5-difluorophenyl)ethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (5) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-phenylpropan-2-yl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (6) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylpropyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (7) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-(2-fluorophenyl)propan-2-yl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (8) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-(3-chlorophenyl)ethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (9) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-(2,4-difluorophenyl)ethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (10) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(prop-1-yn-1-yl)-N-((S)-2,2,2-trifluoro-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (11) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-(2-phenylpropan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,
- (12) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-(2,3-difluorophenyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(13) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3-methoxy-3-methylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(14) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(but-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(15) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-(2-fluorophenyl)propan-2-yl)-6-(3-methylbut-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(16) 7-((3R,5S)-1-acryloyl-5-ethylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(17) 7-((3R,5S)-1-acryloyl-5-ethylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(18) 7-((3R,5R)-1-acryloyl-5-(methoxymethyl)pyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, and

(19) 7-((3R,5R)-1-acryloyl-5-(ethoxymethyl)pyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[0089]

A preferred example of the compound represented by the formula (I) or the formula (II) may be a compound selected from the following (1) to (3), or a salt thereof.

(1) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(2) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, and

(3) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3,3-dimethylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[0090]

The most preferable pyrimidine compound of the present invention is 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[0091]


< Method for producing compound represented by formula (I) >

The compound according to the present invention can be produced by, for example, the following production method or the methods described in the Examples. However, the method for producing the compound according to the present invention is not limited to these examples.

[0092]

The compounds (I) and (II) of the present invention can be produced by applying, for example, the following production method.

< Production Method >



In the above process, L₁, L₂, and L₃, which are the same or different, each represent a leaving group; P₁ and P₂, which are the same or different, each represent a protective group; and other symbols are as defined above.

[0093]

< Step 1 >

This step is a method of obtaining a compound represented by the formula 3 by performing a Mitsunobu reaction between a compound represented by the formula 1 and a compound represented by the formula 2 that is a commercially available

compound or can be produced by a known method. The Mitsunobu reaction is generally carried out in the presence of a Mitsunobu reagent and a phosphine reagent.
[0094]

The compound represented by the formula 2 (in the formula 2, P₁ represents a protective group for an amino group) can be used in an amount of 1 to 10 equivalents, and preferably 1 to 3 equivalents, based on the amount of the compound represented by the formula 1 (1 mole).

[0095]

The "protective group for an amino group" is not particularly limited, as long as it has a protective function. Examples of the protective group for an amino group may include: aralkyl groups, such as a benzyl group, a p-methoxybenzyl group, a 3,4-dimethoxybenzyl group, an o-nitrobenzyl group, a p-nitrobenzyl group, a benzhydryl group, a trityl group, and a cumyl group; lower alkanoyl groups, such as, for example, a formyl group, an acetyl group, a propionyl group, a butyryl group, a pivaloyl group, a trifluoroacetyl group, and a trichloroacetyl group; for example, benzoyl groups; arylalkanoyl groups, such as, for example, a phenylacetyl group and a phenoxyacetyl group; lower alkoxycarbonyl groups, such as, for example, a methoxycarbonyl group, an ethoxycarbonyl group, a propyloxycarbonyl group, and a tert-butoxycarbonyl group; aralkyloxycarbonyl groups, such as, for example, a p-nitrobenzyloxycarbonyl group and a phenethyloxycarbonyl group; lower alkylsilyl groups, such as, for example, a trimethylsilyl group and a tert-butyldimethylsilyl group; for example, tetrahydropyranyl groups; for example, trimethylsilylethoxymethyl groups; lower alkylsulfonyl groups, etc., such as, for example, a methylsulfonyl group, an ethylsulfonyl group, and a tert-butylsulfonyl group; lower alkylsulfinyl groups, etc., such as for example, a tert-butylsulfinyl group; arylsulfonyl groups, etc., such as, for example, a benzenesulfonyl group and a toluenesulfonyl group; and imide groups, such as, for example, a phthalimide group.

Among these, a trifluoroacetyl group, an acetyl group, a tert-butoxycarbonyl group, a benzyloxycarbonyl group, a trimethylsilylethoxymethyl group, or a cumyl group is particularly preferable.

[0096]

As a Mitsunobu reagent, diethyl azodicarboxylate, diisopropyl azodicarboxylate or the like is used. Such a Mitsunobu reagent is used in an amount of generally approximately 1 to 100 moles, and preferably approximately 1 to 10 moles, based on the compound represented by the formula 1 (1 mole).

[0097]

As a phosphine reagent, triphenylphosphine, tributylphosphine, trifurylphosphine or the like is used. Such a phosphine reagent is used in an amount of generally approximately 1 to 100 moles, and preferably approximately 1 to 10 moles, based on the compound represented by the formula 1 (1 mole).

[0098]

The solvent is not particularly limited, as long as it does not affect the reaction. Examples of the solvent may include hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), water, and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 100° C.

[0099]

The thus obtained compound represented by the formula 3 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0100]

< Step 2 >

This step is a method of obtaining a compound represented by the formula 4 by allowing the compound represented by the formula 3 to react with ammonia or a salt thereof.

[0101]

The ammonia or a salt thereof can be used in an amount of 1 to 1000 equivalents, and preferably 1 to 100 equivalents, based on the amount of the compound represented by the formula 3 (1 mole).

[0102]

The solvent is not particularly limited, as long as it does not affect the reaction. Examples of the solvent may include hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), water, and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 150° C.

[0103]

The thus obtained compound represented by the formula 4 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0104]

< Step 3 >

This step is a method of obtaining a compound represented by the formula 5 by reacting the compound represented by the formula 4 under a carbon monoxide

atmosphere, for example, in the presence of a transition metal catalyst, a base and alcohol.

[0105]

In this step, the pressure of the carbon monoxide is generally from 1 to 20 atmospheres, and preferably 1 to 10 atmospheres.

[0106]

Examples of the alcohol may include methanol, ethanol, propanol, isopropanol, diethylaminoethanol, isobutanol, 4-(2-hydroxyethyl)morpholine, 3-morpholinopropanol, and diethylaminopropanol.

[0107]

The alcohol is used in an amount of generally approximately 1 to 100 moles, and preferably approximately 1 to 50 moles, based on the amount of the compound represented by the formula 4 (1 mole).

[0108]

Examples of the transition metal catalyst used herein may include palladium catalysts (e.g., palladium acetate, palladium chloride, tetrakis(triphenylphosphine) palladium, palladium carbon, etc.). A ligand (e.g., triphenylphosphine, tri-tert-butylphosphine, etc.) may be added, as necessary. The amount of the transition metal catalyst used is different depending on the type of the catalyst. The transition metal catalyst is used in an amount of generally approximately 0.0001 to 1 mole, and preferably approximately 0.01 to 0.5 moles, based on the amount of the compound 4 (1 mole). The ligand is used in an amount of generally approximately 0.0001 to 4 moles, and preferably approximately 0.01 to 2 moles, based on the amount of the compound represented by the formula 4 (1 mole).

[0109]

Examples of the base may include organic amines (e.g., trimethylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, 1,8-

diazabicyclo[5,4,0]undec-7-ene, pyridine, N,N-dimethylaniline, etc.), alkaline metal salts (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, potassium phosphate, sodium hydroxide, potassium hydroxide, etc.), metal hydrides (e.g., potassium hydride, sodium hydride, etc.), alkaline metal alkoxides (e.g., sodium methoxide, sodium ethoxide, sodium-tert-butoxide, potassium-tert-butoxide, etc.), and alkaline metal disilazides (e.g., lithium disilazide, sodium disilazide, potassium disilazide, etc.). Among others, alkaline metal salts such as potassium carbonate, cesium carbonate, sodium phosphate, and potassium phosphate, alkaline metal alkoxides such as sodium-tert-butoxide and potassium-tert-butoxide, organic amines such as triethylamine and diisopropylethylamine, and the like are preferable. The base is used in an amount of generally approximately 0.1 to 50 moles, and preferably approximately 1 to 20 moles, based on the amount of the compound represented by the formula 4 (1 mole).

[0110]

The solvent is not particularly limited, as long as it does not affect the reaction. Examples of the solvent may include hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, N-methylpyrrolidone, etc.), water, and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 150° C.

[0111]

After completion of this reaction, an ester form corresponding to the used alcohol, or a mixture of the ester form and the compound represented by the formula

5 is subjected to a hydrolysis reaction, so that it can be converted to the compound represented by the formula 5.

[0112]

As such a base, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, or the like is preferably used. The base is used in an amount of generally approximately 0.5 to 100 moles, and preferably approximately 1 to 10 moles, based on the amount of the compound represented by the formula 4 (1 mole).

[0113]

The solvent is not particularly limited, as long as it does not affect the reaction. For example, water, methanol, ethanol, isopropanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide and the like can be used alone or in combination. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 100° C.

[0114]

The thus obtained compound represented by the formula 5 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0115]

< Step 4 >

This step is a method of obtaining a compound represented by the formula 6 (wherein P₂ represents a protective group for a carboxyl group) by introducing a protective group into the compound represented by the formula 5. Protection can be carried out according to a generally known method, for example, the method described in Protective Groups in Organic Synthesis third edition, T. W. Greene and P. G. M. Wuts, John Wiley & Sons (1999), or a method equivalent thereto.

[0116]

The "protective group for a carboxyl group" is not particularly limited, as long as it has a protective function. Examples of the protective group for a carboxyl group may include: lower alkyl groups, such as, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, and a tert-butyl group; halo lower alkyl groups, such as, for example, a 2,2,2-trichloroethyl group; lower alkenyl groups, such as, for example, an allyl group; for example, a trimethylsilylethoxymethyl group; and aralkyl groups, such as, for example, a benzyl group, a p-methoxybenzyl group, a p-nitrobenzyl group, a benzhydryl group, and a trityl group. In particular, a methyl group, an ethyl group, a tert-butyl group, an allyl group, a benzyl group, a p-methoxybenzyl group, or a trimethylsilylethoxymethyl group is preferable.

[0117]

In the present reaction, a protective group such as, for example, a tert-butyl ester group, a methyl ester group, or an ethyl ester group, is preferably introduced.

[0118]

The protective group agent used in the present reaction may be, for example, 2-tert-butyl-1,3-diisopropylisourea. Such a protective group agent is used in an amount of generally approximately 1 to 50 moles, and preferably approximately 1 to 10 moles, based on the amount of the compound represented by the formula 5 (1 mole).

[0119]

The solvent is not particularly limited, as long as it does not affect the reaction. Examples of the solvent may include hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, tert-butyl methyl ether, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.),

water, and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 100° C.

[0120]

The thus obtained compound represented by the formula 6 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0121]

< Step 5 >

This step is a method of obtaining a compound represented by the formula 7 (wherein L₃ represents a halogen atom) by halogenating the compound represented by the formula 6. Halogenation can be carried out by a method using fluorine, chlorine, bromine, iodine, etc., or by a method using N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, etc. In the present reaction, the method using N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, etc. is preferable.

[0122]

N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, etc. can be used in an amount of 1 to 10 equivalents, and preferably 1 to 3 equivalents, based on the amount of the compound represented by the formula 6 (1 mole).

[0123]

The solvent is not particularly limited, as long as it does not affect the reaction. Examples of the solvent may include hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), water, and mixtures thereof.

The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 100°.

[0124]

The thus obtained compound represented by the formula 7 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0125]

< Step 6 >

This step is a method of obtaining a compound represented by the formula 8 by removing the protective group for an amino group (P₁ in the formula 7) from the compound represented by the formula 7 (deprotection). Such deprotection can be carried out according to a generally known method, for example, the method described in Protective Groups in Organic Synthesis third edition, T. W. Greene and P. G. M. Wuts, John Wiley & Sons (1999), or a method equivalent thereto.

[0126]

The protective group may be, for example, tert-butyloxycarbonyl. When such a tert-butyloxycarbonyl group is used, for example, as a protective group, deprotection is preferably carried out under acidic conditions. Examples of the acid used herein may include hydrochloric acid, acetic acid, trifluoroacetic acid, sulfuric acid, and tosylic acid.

[0127]

The acid is preferably used in an amount of approximately 1 to 100 equivalents based on the amount of the compound represented by the formula 7 (1 mole).

[0128]

The solvent used in the reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent used herein may include alcohols (e.g., methanol, etc.), hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to 100°C, and preferably 0°C to 50°.

[0129]

The thus obtained compound represented by the formula 8 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0130]

< Step 7 >

This step is a method of obtaining a compound represented by the formula 9 by performing an amidation reaction between an amino group of the compound represented by the formula 8 and acrylic acid halide or acrylic acid anhydride.

[0131]

In the case of using acrylic acid halide or acrylic acid anhydride, such acrylic acid halide or acrylic acid anhydride is used in an amount of generally approximately 0.5 to 10 moles, and preferably approximately 1 to 5 moles, based on the amount of the compound represented by the formula 8 (1 mole). It is to be noted that the present acrylic acid halide or acrylic acid anhydride can be obtained as a commercially available product or can be produced according to a known method.

[0132]

In addition, a base can be added, as necessary. Examples of the base may include organic amines (e.g., trimethylamine, triethylamine, isopropylethylamine, diisopropylethylamine, N-methylmorpholine, 1,8-diazabicyclo[5,4,0]undec-7-ene, pyridine, N,N-dimethylaniline, etc.), alkaline metal salts (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, potassium phosphate, sodium hydroxide, potassium hydroxide, etc.), metal hydrides (e.g., potassium hydride, sodium hydride, etc.), and alkaline metal alkoxides (e.g., sodium methoxide, sodium ethoxide, sodium-tert-butoxide, potassium-tert-butoxide, etc.). The base is used in an amount of generally approximately 1 to 100 moles, and preferably approximately 1 to 10 moles, based on the amount of the compound represented by the formula 8 (1 mole).

[0133]

The solvent used in the reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent used herein may include alcohols (e.g., methanol, etc.), hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, , etc.), and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 100° C.

[0134]

The thus obtained compound represented by the formula 9 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0135]

< Step 8 >

This step is a method of obtaining a compound represented by the formula 10 by performing a Sonogashira reaction between the compound represented by the formula 9 and an acetylene derivative that is a commercially available product or can be produced by a known method.

[0136]

The acetylene derivative can be used in an amount of 1 to 50 equivalents, and preferably 1 to 10 equivalents, based on the amount of the compound represented by the formula 9 (1 mole).

[0137]

Examples of the transition metal catalyst used herein may include palladium catalysts (e.g., palladium acetate, palladium chloride, tetrakis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)dipalladium, etc.), and nickel catalysts (e.g., nickel chloride, etc.). As necessary, a ligand (e.g., triphenylphosphine, tri-tert-butylphosphine, etc.) may be added, and a copper catalyst (e.g., copper iodide, copper bromide, or copper chloride) or the like may be used as a co-catalyst. The amount of the transition metal catalyst used is different depending on the type of the catalyst. The transition metal catalyst is used in an amount of generally approximately 0.0001 to 1 mole, and preferably approximately 0.01 to 0.5 moles, based on the amount of the compound represented by the formula 9 (1 mole). The ligand is used in an amount of generally approximately 0.0001 to 4 moles, and preferably approximately 0.01 to 2 moles, based on the amount of the compound represented by the formula 9 (1 mole). The copper catalyst is used in an amount of generally approximately 0.0001 to 4 moles, and preferably approximately 0.010 to 2 moles, based on the amount of the compound represented by the formula 9 (1 mole).

[0138]

Examples of the base may include organic amines (e.g., trimethylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, 1,8-diazabicyclo[5,4,0]undec-7-ene, pyridine, N,N-dimethylaniline, etc.), alkaline metal salts (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, potassium phosphate, sodium hydroxide, potassium hydroxide, etc.), metal hydrides (e.g., potassium hydride, sodium hydride, etc.), alkaline metal alkoxides (e.g., sodium methoxide, sodium ethoxide, sodium-tert-butoxide, potassium-tert-butoxide, etc.), and alkaline metal disilazide (e.g., lithium disilazide, sodium disilazide, potassium disilazide, etc.). Among these, preferred examples of the base may include: alkaline metal salts, such as potassium carbonate, cesium carbonate, sodium phosphate, and potassium phosphate; alkaline metal alkoxides, such as sodium-tert-butoxide and potassium-tert-butoxide; and organic amines, such as triethylamine and diisopropylethylamine. The base is used in an amount of generally approximately 0.1 to 10 moles, and preferably approximately 1 to 5 moles, based on the amount of the compound represented by the formula 9 (1 mole).

[0139]

The solvent is not particularly limited, as long as it does not affect the reaction. Examples of the solvent may include hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, etc.), water, and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 150° C.

[0140]

The thus obtained compound represented by the formula 10 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0141]

< Step 9 >

This step is a method of obtaining a compound represented by the formula 11 by deprotecting the protective group for a carboxyl group (P_2 in the formula 10) of the compound represented by the formula 10. Deprotection can be carried out according to a generally known method, for example, the method described in Protective Groups in Organic Synthesis third edition, T. W. Greene and P. G. M. Wuts, John Wiley & Sons (1981), or a method equivalent thereto.

[0142]

The protective group may be, for example, tert-butyl ester. When such a tert-butyl ester group is used as a protective group, for example, deprotection is preferably carried out under acidic conditions. Examples of the acid used herein may include hydrochloric acid, acetic acid, trifluoroacetic acid, sulfuric acid, and tosylic acid.

[0143]

The acid is preferably used in an amount of approximately 1 to 100 equivalents based on the amount of the compound represented by the formula 10 (1 mole).

[0144]

The solvent used in the reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent used herein may include alcohols (e.g., methanol, etc.), hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), aprotic

polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, , etc.), and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to 100°C, and preferably 0°C to 50°.

[0145]

The thus obtained compound represented by the formula 11 can be isolated and purified by known separation and purification means, or can be subjected to the subsequent step without isolation and purification.

[0146]

< Step 10 >

This step is a method of obtaining a compound represented by the formula (I) by performing an amidation reaction between a carboxyl group of the compound represented by the formula 11 and an amine that is a commercially available product or can be produced by a known method.

[0147]

Amidation can be carried out according to a conventionally known method. Examples of the amidation method may include a method of performing the reaction in the presence of a condensing agent, and a method comprising activating a carboxylic acid portion according to a conventionally known method to obtain a reactive derivative, and then performing amidation between the derivative and an amine (for both methods, see "*Peptide Gosei no Kiso to Jikken* (Principle of Peptide Synthesis and Experiments)" (Nobuo IZUMIYA et al., Maruzen Co., Ltd., 1983)).

[0148]

Examples of the condensing agent may include N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC), diphenylphosphoryl azide (DPPA), benzotriazol-1-yl-oxytrisdimethylaminophosphonium

hexafluorophosphate (BOP), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 7-azabenzotriazol-1-yl-oxytripyrrolidinophosphonium phosphate (PyAOP), bromotrispyrrolidinophosphonium hexafluorophosphate (BroP), chlorotris(pyrrolidin-1-yl)phosphonium hexafluorophosphate (PyCroP), 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), O-(azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and 4-(5,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholine hydrochloride (DMTMM). Examples of the additive used at that time may include 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), and N-hydroxysuccinimide (HOSu). Such agents are used in an amount of generally approximately 1 to 100 moles, and preferably approximately 1 to 10 moles, based on the amount of the compound represented by the formula 11 (1 mole).

[0149]

In addition, as necessary, a base can be added. Examples of such a base may include organic amines (e.g., trimethylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, 1,8-diazabicyclo[5,4,0]undec-7-ene, pyridine, N,N-dimethylaniline, etc.), alkaline metal salts (e.g., sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, potassium phosphate, sodium hydroxide, potassium hydroxide, etc.), metal hydrides (e.g., potassium hydride, sodium hydride, etc.), and alkaline metal alkoxides (e.g., sodium methoxide, sodium ethoxide, sodium-tert-butoxide, potassium-tert-butoxide, etc.). The base is used in an amount of generally approximately 1 to 100 moles, and preferably approximately 1 to 10 moles, based on the amount of the compound represented by the formula 11 (1 mole).

[0150]

The solvent used in the reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent used herein may include alcohols (e.g., methanol, etc.), hydrocarbons (e.g., benzene, toluene, xylene, etc.), halogenated hydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile, etc.), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, , etc.), and mixtures thereof. The reaction time is 0.1 to 100 hours, and preferably 0.5 to 24 hours. Thereafter, the reaction temperature is 0°C to the temperature at which the solvent is boiled, and preferably 0°C to 100° C.

[0151]

The thus obtained compounds (I) and (II) can be isolated and purified according to known separation and purification means, such as, for example, concentration , vacuum concentration, crystallization, solvent extraction, re-precipitation, or chromatography.

[0152]

In the above-described production method, the steps ranging from the "introduction of a protective group into a carboxyl group of the compound represented by the formula 5" (Step 4) to the "amidation reaction between a carboxyl group of the compound represented by the formula 11 and an amine that is a commercially available product or can be produced by a known method" (Step 10) are successively carried out in this order. However, the order of performing these steps can be changed. Moreover, the "introduction of a protective group into a carboxyl group of the compound represented by the formula 5" (Step 4) and the "removal of the protective group for a carboxy group from the compound represented by the formula 10" (Step 9) can be omitted.

[0153]

Specifically, individual steps are carried out in the order of the "amidation reaction between a carboxyl group of the compound represented by the formula 11 and an amine that is a commercially available product or can be produced by a known method" (Step 10), the "halogenation of the compound represented by the formula 6" (Step 5), the "removal of the protective group for an amino group from the compound represented by the formula 7" (Step 6), the "amidation reaction between an amino group of the compound represented by the formula 8 and acrylic acid halide or acrylic acid anhydride" (Step 7), and the "Sonogashira reaction between the compound represented by the formula 9 and an acetylene derivative that is a commercially available product or can be produced by a known method, when L3 of the compound represented by the formula 9 has a leaving group such as halogen" (Step 8), so that the concerned compound can be induced to the compounds represented by the formulae (I) and (II). The conditions applied in individual steps are the same as those as described above.

[0154]

When the compound of the present invention has an isomer, such as an optical isomer, a stereoisomer, a rotational isomer, or a tautomer, all of these isomers or mixtures thereof are included in the compound of the present invention, unless otherwise stated. For example, when the compound of the present invention has an optical isomer, both a racemate, and an optical isomer obtained as a result of racemic resolution are included in the compound of the present invention, unless otherwise stated.

[0155]

The salt of the compound of the present invention means a pharmaceutically acceptable salt, and it may be, for example, a base-added salt or an acid-added salt.

[0156]

The pyrimidine compound of the present invention or a salt thereof also includes a prodrug. The "prodrug" means a compound that is converted to the compound of the present invention or a salt thereof as a result of the reaction with an enzyme, stomach acid, etc. under physiological conditions in a living body; namely, a compound that enzymatically causes oxidation, reduction, hydrolysis, etc., so that it is converted to the compound of the present invention or a salt thereof, or a compound that causes hydrolysis, etc. with stomach acid or the like, so that it is converted to the compound of the present invention or a salt thereof. Otherwise, it may also be a compound that is converted to the compound of the present invention or a salt thereof under physiological conditions as described in "*Iyaku hin no Kaihatsu* (Development of Pharmaceutical Products)," Hirokawa Shoten, 1990, Vol. 7, *Bunshi Sekkei* (Molecular Designing), pp. 163 to 198.

[0157]

The pyrimidine compound of the present invention or a salt thereof may be an amorphous material or a crystal. Although the crystal form thereof may be a single crystal or a polymorphic mixture, they are included in the compound of the present invention or a salt thereof. The crystal can be produced by crystallizing the compound of the present invention or a salt thereof, applying a known crystallization method. The compound of the present invention or a salt thereof may be either a solvate (e.g., a hydrate, etc.), or a non-solvate, and both of them are included in the compound of the present invention or a salt thereof. Compounds labeled with radioisotopes (e.g., ^3H , ^{14}C , ^{35}S , ^{125}I , etc.) and the like are also included in the compound of the present invention or a salt thereof.

[0158]

The compound of the present invention or a salt thereof has excellent EGFR inhibitory activity. Accordingly, the compound of the present invention or a salt thereof is useful as an antitumor agent against malignant tumor having EGFR

overexpression, EGFR gene amplification, or EGFR mutation, etc. In addition, since significant weight reduction was not found in mice, the present compound or a salt thereof is advantageous in that it has a few side effects.

In the present description, the term "EGFR" includes the EGFR of a human or a non-human mammal, and it is preferably human EGFR. The NCBI Gene ID for the human EGFR is 1956. Furthermore, the term "EGFR" includes isoforms.

[0159]

Since the compound of the present invention or a salt thereof has excellent EGFR inhibitory activity, it is useful as a medicament for preventing or treating disease associated with EGFR.

[0160]

The "disease associated with EGFR" means disease, in which a reduction in the incidence, or the remission, alleviation and/or complete recovery of the symptoms thereof is achieved by deleting, suppressing and/or inhibiting the function of EGFR. Examples of such disease may include malignant tumors, but are not limited thereto. Preferred examples of the disease may include malignant tumors having EGFR overexpression, EGFR gene amplification, or EGFR mutation.

[0161]

One embodiment of the present invention provides a therapeutic agent for a disease associated with EGFR, comprising the compound of the present invention or a salt thereof. One embodiment of the present invention provides an EGFR inhibitor comprising the compound of the present invention or a salt thereof. One embodiment of the present invention provides a therapeutic agent for EGFR-positive tumor, comprising the compound of the present invention or a salt thereof. One embodiment of the present invention provides the compound of the present invention or a salt thereof for treating a disease associated with EGFR. One embodiment of the present invention provides use of the compound of the present invention or a salt

thereof for treating a disease associated with EGFR. One embodiment of the present invention provides use of the compound of the present invention or a salt thereof for producing a therapeutic agent for a disease associated with EGFR. One embodiment of the present invention provides a method for treating a disease associated with EGFR, comprising administering an effective amount of the compound of the present invention or a salt thereof to a subject in need thereof. One embodiment of the present invention provides the compound of the present invention or a salt thereof for treating EGFR-positive tumor. One embodiment of the present invention provides use of the compound of the present invention or a salt thereof for treating EGFR-positive tumor. One embodiment of the present invention provides use of the compound of the present invention or a salt thereof for producing a therapeutic agent for EGFR-positive tumor. One embodiment of the present invention provides a method for treating EGFR-positive tumor, comprising administering an effective amount of the compound of the present invention or a salt thereof to a subject in need thereof.

[0162]

The compound according to one embodiment of the present invention or a salt thereof inhibits wild-type EGFR, and mutant EGFR having an insertion mutation, a point mutation, or a deletion mutation, etc. One embodiment of the present invention provides a compound having inhibitory activity against wild-type EGFR and mutant EGFR, or a salt thereof, or a medicament or a pharmaceutical composition comprising the same. One embodiment of the present invention provides an inhibitor for wild-type EGFR and mutant EGFR, comprising the compound of the present invention or a salt thereof. One embodiment of the present invention provides a method for inhibiting wild-type EGFR and mutant EGFR, comprising administering an effective amount of the compound of the present invention or a salt thereof to a subject in need thereof. One embodiment of the

present invention provides use of the compound of the present invention or a salt thereof for producing an inhibitor for wild-type EGFR and mutant EGFR. One embodiment of the present invention provides the compound of the present invention or a salt thereof for use as an inhibitor for wild-type EGFR and mutant EGFR. One embodiment of the present invention provides use of the compound of the present invention or a salt thereof for inhibiting wild-type EGFR and mutant EGFR. Another embodiment of the present invention provides use of the compound of the present invention or a salt thereof for preventing or treating diseases associated with wild-type EGFR and mutant EGFR.

[0163]

The human wild-type EGFR gene is shown in, for example, SEQ ID NO: 1. The human wild-type EGFR protein consists of the amino acid sequence set forth in, for example, SEQ ID NO: 2. The nucleotide sequence information of the human wild-type EGFR gene and the amino acid sequence information of the human wild-type EGFR protein can be obtained from, for example, NCBI Reference Sequence: NM_005228 and NCBI Reference Sequence: NP_005219, respectively.

[0164]

In several embodiments, the pyrimidine compound of the present invention or a salt thereof exhibits inhibitory activity against mutant EGFR. In the present description, "mutant EGFR" is EGFR having one or more activating mutations or resistance acquiring mutations, such as insertion mutations point mutations, or deletion mutations, in exon 18 region, exon 19 region, exon 20 region, exon 21 region or the like of human wild-type EGFR.

[0165]

In the present description, "exon 18" corresponds to a region from positions 688 to 728 in the amino acid sequence of the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2).

[0166]

In the present invention, "exon 18 mutation" refers to a point mutation or a deletion mutation in exon 18 region resulting in an amino acid mutation in the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2). Examples of the point mutation in exon 18 include point mutation E709X or G719X in exon 18 region, which substitutes glutamic acid at position 709 or glycine at position 719 with any amino acid. Examples of E709X include point mutation E709K in exon 18 region, which substitutes glutamic acid at position 709 with lysine, and point mutation E709A in exon 18 region, which substitutes glutamic acid at position 709 with alanine. Examples of G719X include point mutation G719A in exon 18 region, which substitutes glycine at position 719 with alanine, point mutation G719S in exon 18 region, which substitutes glycine at position 719 with serine, and point mutation G719C in exon 18 region, which substitutes glycine at position 719 with cysteine. The deletion mutation in exon 18 region encompasses not only a mutation in exon 18 region, which deletes some amino acids, but also a mutation therein, which inserts any one or more amino acids in addition to the amino acid deletion. Examples of the deletion mutation in exon 18 include a mutation in exon 18 region, which deletes glutamic acid at position 709 and threonine at position 710 and then inserts aspartic acid (Del E709-T710insD).

[0167]

In the present description, "exon 19" corresponds to a region from positions 729 to 761 in the amino acid sequence of the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2).

[0168]

In the present description, "exon 19 mutation" refers to a mutation in exon 19 region, which deletes one or more amino acids in the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2).

The deletion mutation in exon 19 region encompasses not only a mutation in exon 19 region, which deletes some amino acids, but also a mutation therein, which inserts any one or more amino acids in addition to the amino acid deletion. Examples of the exon 19 deletion mutation include a mutation in exon 19 region, which deletes 5 amino acids from glutamic acid at position 746 to alanine at position 750 (Del E746-A750 (or also referred to as d746-750)), a mutation in exon 19 region, which deletes 7 amino acids from leucine at position 747 to proline at position 753 and then inserts serine (Del L747-P753insS), a mutation in exon 19 region, which deletes 5 amino acids from leucine at position 747 to threonine at position 751 (Del L747-T751), and a mutation in exon 19 region, which deletes 4 amino acids from leucine at position 747 to alanine at position 750 and then inserts proline (Del L747-A750insP). In one preferred embodiment of the present invention, the exon 19 deletion mutation is a mutation in exon 19 region, which deletes 5 amino acids from glutamic acid at position 746 to alanine at position 750 (Del E746-A750).

[0169]

In the present description, "exon 20" corresponds to a region from positions 762 to 823 in the amino acid sequence of the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2).

[0170]

In the present invention, "exon 20 mutation" refers to a point mutation, an insertion mutation, a deletion mutation, or the like in exon 20 region resulting in an amino acid mutation in the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2). Examples of the exon 20 mutation include A763insFQEA, A767insASV, S768dupSVD, V769insASV, D770insNPG, D770insSVD, and D773insNPH (Nature medicine,24,p638-646,2018). In one preferred embodiment of the present invention, the exon 20 mutation is one or

more insertion mutations or point mutations selected from V769_D770insASV, D770_N771insNPG, D770_N771insSVD, H773_V774insNPH, and T790M.

[0171]

In the present description, "exon 21" corresponds to a region from positions 824 to 875 in the amino acid sequence of the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2).

[0172]

In the present invention, "exon 21 mutation" refers to a point mutation in exon 21 region resulting in an amino acid mutation in the human wild-type EGFR protein (e.g., a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2). Examples of the point mutation in exon 21 include point mutations in exon 21 region, which substitute one amino acid and preferably include position mutation L858X or L861X in exon 21 region, which substitutes leucine at position 858 or leucine at position 861 with any amino acid. Examples of L858X include point mutation L858R in exon 21 region, which substitutes leucine at position 858 with arginine. Examples of L861X include point mutation L861Q in exon 21 region, which substitutes leucine at position 861 with glutamine. In one preferred embodiment of the present invention, the point mutation in exon 21 is L858R.

[0173]

In several embodiments, with regard to a mutation in a certain EGFR isoform, even when position of the mutation is different from position of an amino acid shown in SEQ ID NO: 2 due to deletion or insertion of an amino acid(s), it is understood that the mutation is the same as the mutation at a position corresponding to position of the amino acid shown in SEQ ID NO: 2. Hence, for example, the threonine at position 790 in the EGFR shown in SEQ ID NO: 2 corresponds to threonine at position 745 in EGFR consisting of the amino acid sequence set forth in SEQ ID NO: 4. For example, the term "T790M" means that the threonine at position 790 in the

EGFR shown in SEQ ID NO: 2 is mutated to methionine. Since such "T790M" is at a position corresponding to the amino acid at position 745 in EGFR consisting of the amino acid sequence set forth in SEQ ID NO: 4, "T745M" in the EGFR consisting of the amino acid sequence set forth in SEQ ID NO: 4 corresponds to "T790M" in the EGFR shown in SEQ ID NO: 2. For example, the threonine at position 790 in the EGFR shown in SEQ ID NO: 2 corresponds to threonine at position 523 in EGFR consisting of the amino acid sequence set forth in SEQ ID NO: 6. For example, the term "T790M" means that the threonine at position 790 in the EGFR shown in SEQ ID NO: 2 is mutated to methionine. Since such "T790M" is at a position corresponding to the amino acid at position 523 in EGFR consisting of the amino acid sequence set forth in SEQ ID NO: 6, "T523M" in the EGFR consisting of the amino acid sequence set forth in SEQ ID NO: 6 corresponds to "T790M" in the EGFR shown in SEQ ID NO: 2. Besides, the position of an amino acid in SEQ ID NO: 2 that corresponds to a certain amino acid in a certain EGFR isoform can be confirmed by Multiple Alignment of BLAST.

[0174]

SEQ ID NOs: 1 to 6 are as described below.

EGFR variant 1

Nucleotide sequence (SEQ ID NO: 1)

```
ATGCGACCCTCCGGGACGG
CCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGCGAGTCGGGCTCTGGAGGAAAAGAAAGT
TTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTGAAGATCATTTTCTCAGCCTCCAGAGG
ATGTTCAATAACTGTGAGGTGGTCCTTGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTT
CCTTCTTAAAGACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCC
TTTGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCAGTCTTATCT
AACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTACAGGAAATCCTGCATGGCG
CCGTGCGGTTCAAGCAACAACCCTGCCCTGTGCAACGTGGAGAGCATCCAGTGGCGGGACATAGTCAGCAG
```

TGACTTTCTCAGCAACATGTCGATGGACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGC
TGTHCCAAATGGGAGCTGCTGGGGTGCAGGAGAGGAGAACTGCCAGAACTGACCAAAATCATCTGTGCCC
AGCAGTGCTCCGGGCGCTGCCGTGGCAAGTCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTG
CACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCGAGACGAAGCCACGTGCAAGGACACC
TGCCCCCACTCATGCTCTACAACCCACCACGTACCAGATGGATGTGAACCCCGAGGGCAAATACAGCT
TTGGTGCCACCTGCGTGAAGAAGTGTCCTCGTAATTATGTGGTGACAGATCACGGCTCGTGCGTCCGAGC
CTGTGGGGCCGACAGCTATGAGATGGAGGAAGACGGCGTCCGCAAGTGTAAAGAAGTGCGAAGGGCCTTGC
CGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTA
AACACTTCAAAAAGTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTAGGGGTGACTC
CTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCACAGGG
TTTTTGCTGATTACAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTTGAGAACCTAGAAATCATAC
GCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGACAGTCGTCAGCCTGAACATAACATCCTTGGGATT
ACGCTCCCTCAAGGAGATAAGTGATGGAGATGTGATAATTCAGGAAACAAAATTTGTGCTATGCAAAT
ACAATAAACTGGAAAAAAGTGTGGGACCTCCGGTCAGAAAACCAAATTATAAGCAACAGAGGTGAAA
ACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCGAGGGCTGCTGGGGCCCGGAGCC
CAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGAACCTTCTGGAG
GGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGCCTGCCTCAGGCCA
TGAACATCACCTGCACAGGACGGGGACCAGACAAGTGTATCCAGTGTGCCACTACATTGACGGCCCCCA
CTGCGTCAAGACCTGCCCCGACAGGAGTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCC
GGCCATGTGTGCCACCTGTGCCATCCAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTC
CAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGT
GGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTGGAAGCGCACGCTGCGGAGGCTGCTG
CAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCT
TGAAGGAACTGAATTCAAAAAGATCAAAGTGTGGGCTCCGGTTCGCTTCGGCACGGTGTATAAGGGACT
CTGGATCCCAGAAGGTGAGAAAGTTAAATTTCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCG
AAAGCCAACAAGGAAATCCTCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCC
TGCTGGGCATCTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGA

CTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAG
GGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAA
CACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTGGGTGCGGAAGAGAAAGAATACCA
TGCAGAAGGAGGCAAAGTGCCTATCAAGTGGATGGCATTGGAATCAATTTTACACAGAATCTATACCCAC
CAGAGTGATGTCTGGAGCTACGGGGTGA CTGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACG
GAATCCCTGCCAGCGAGATCTCTCCATCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTAC
CATCGATGTCTACATGATCATGGTCAAGTGTGGATGATAGACGCAGATAGTCGCCCAAAGTTCCGTGAG
TTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCAGCGCTACCTTGTCAATCAGGGGGATGAAAGAA
TGCATTTGCCAAGTCTACAGACTCCAACCTTCTACCGTGCCCTGATGGATGAAGAAGACATGGACGACGT
GGTGGATGCCGACGAGTACCTCATCCACAGCAGGGCTTCTTCAGCAGCCCCCTCCACGTCACGGACTCCC
CTCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAA
GCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCACAGGCGCCTTGACTGAGGA
CAGCATAGACGACACCTTCTCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAGGCCCGCTGGC
TCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCAGCAGAGACCCACACTACCAGG
ACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAACTGTCCAGCCCACCTGTGTCAACAGCAC
ATTGACAGCCCTGCCACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTGGACAACCTGACTACCAG
CAGGACTTCTTTCCAAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAAT
ACCTAAGGGTCGCGCCACAAAGCAGTGAATTTATTGGAGCATGA

[0175]

Amino acid sequence (SEQ ID NO: 2)

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNCEVVLGNLEITYV
QRNYDLSFLKTIQEVAGYVLIALNTVERIPLNLQIRGNMYYENSYALAVLSNYDANKTGLKELPMRNL
QEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNLHLSGSCQKCDPSCPNGSCWGAGEENCQKL
TKIIAQQCSGRGRGKSPSDCCHNQCAAGCTGPRESCLVCRKFRDEATCKDTCPLMLYNPTTYQMDVN
PEGKYSFGATCVKKCPRNYVVDHGS CVRACGADSYEMEEDGVRKCKCEGPCRKVCNGIGIGEFKDSLS
INATNIKHFKNCTISISGLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGR TKQHGFSLAVVSLNITSLGLRSLKEISDGDVVISGNKNLCYANTINWKKLFGTSGQKTKI

ISNRGENSKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGECVDKCNLLEGEPREFVENSECIQCHP
ECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTG
PGLEGCPNGPKIPSIATGMVGAALLLVVALGIGLFMRRRHIVRKRTLRLQLQERELVEPLTPSGEAPN
QALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVD
NPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTWELMTF
GSKPYDGIPASEISSILEKGERLPQPPICITIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLV
IQGDERMHLPSPTDSNFYRALMDEEDMDDVDADEYLIPQQGFFSSPSTSRTPLSSLSATSNNSTVACI
DRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPS
RDPHYQDPHSTAVGNPEYLNTPQTCVNSTFDSPAHWAKGSHQISLDNPDYQQDFFPKEAKPNGIFKGS
TAENAEYLRVAPQSSEFIGA

[0176]

EGFR variant 5

Nucleotide sequence (SEQ ID NO: 3)

ATGCGACCTCCGGGACGG
CCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGCGAGTCGGGCTCTGGAGGAAAAGAAAGT
TTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACCTTTGAAGATCATTTTCTCAGCCTCCAGAGG
ATGTTCAATAACTGTGAGGTGGTCCTTGGAATTGGAATTACCTATGTGCAGAGGAATTATGATCTTT
CCTTCTTAAAGACCATCCAGGAGGTGGCTGGTTATGTCTCATTGCCCTCAACACAGTGAGCGAATTCC
TTTGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCAGTCTTATCT
AACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCATGAGAAATTTACAGGGCCAAAAGTGTGATC
CAAGCTGTCCCAATGGGAGCTGCTGGGGTGCAGGAGAGGAGAACTGCCAGAACTGACCAAAATCATCTG
TGCCACAGCAGTGCTCCGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCA
GGCTGCACAGGCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCGAGACGAAGCCACGTGCAAGG
ACACCTGCCCCCACTCATGCTCTACAACCCACCACGTACCAGATGGATGTGAACCCCGAGGGCAAATA
CAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTGGTGACAGATCACGGCTCGTGCGTC
CGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAAGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGC

CTTGCCGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAA
TATTAAACACTTCAAAAACCTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGT
GACTCCTTCACACATACTCCTCCTCTGGATCCACAGGAAGTGGATATTCTGAAAACCGTAAAGGAAATCA
CAGGGTTTTTGCTGATTCAAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTTGAGAACCTAGAAAT
CATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTCGTCAGCCTGAACATAACATCCTTG
GGATTACGCTCCCTCAAGGAGATAAGTGATGGAGATGTGATAATTCAGGAAACAAAAATTTGTGCTATG
CAAATACAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGG
TGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTTGCTGCTCCCCGAGGGCTGCTGGGGCCCCG
GAGCCCAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTC
TGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGCCTGCCTCA
GGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACCTGTATCCAGTGTGCCCCACTACATTGACGGC
CCCCACTGCGTCAAGACCTGCCCCGCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAG
ACGCCGGCCATGTGTGCCACCTGTGCCATCCAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGG
CTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTG
GTGGTGGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGGAGGC
TGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAG
GATCTTGAAGGAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCCGGTGCCTTCGGCACGGTGTATAAG
GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCTCGCTATCAAGGAATTAAGAGAAGCAACAT
CTCCGAAAGCCAACAAGGAAATCCTCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTG
CCGCCTGCTGGGCATCTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTC
CTGGACTATGTCCGGGAACACAAAGACAATATTGGCTCCAGTACCTGCTCAACTGGTGTGTGCAGATCG
CAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGT
GAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTGGGTGCGGAAGAGAAAGAA
TACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGGATGGCATTGGAATCAATTTACACAGAATCTATA
CCCACCAGAGTGATGTCTGGAGCTACGGGGTGACTGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATA
TGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATA
TGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAGTTCC

GTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCAGCGCTACCTTGTCATTACAGGGGGATGA
AAGAATGCATTTGCCAAGTCCTACAGACTCCAACCTCTACCGTGCCCTGATGGATGAAGAAGACATGGAC
GACGTGGTGGATGCCGACGAGTACCTCATCCACAGCAGGGCTTCTTCAGCAGCCCCCTCCACGTCACGGA
CTCCCCCTCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCAATTGATAGAAATGGGCT
GCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCACAGGCGCCTTGACT
GAGGACAGCATAGACGACACCTTCTCCAGTGCCTGGTGAGTGGCTTGCTTGAAACAGTCTGCTCTCT
CAACCTCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCTCCAGCATCTCC
AGAGGGGGAAACAGTGGCAGATTTCAGACACAGTGA

[0177]

Amino acid sequence (SEQ ID NO: 4)

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTLGTGFEDHFLSLQRMFNCEVVLGNLEITYV
QRNYDLSFLKTIQEVAGYVLIALNTVERIPLNLQIRGNMYYENSYALAVLSNYDANKTGLKELPMRNL
QQQKCDPSPNGSCWGAGEENCQKLTKIICAQQCSGRGRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFR
DEATCKDTCPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVDHGSVCVRACGADSYEMEEDGVRK
CKKCEGPCRKVCNGIGIGEFKDSLSINATNIHKFNCTSSISGDLHILPVAFRGDSFTHTPPLDPQELDIL
KTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRKQHGQFSLAVVSLNITSLGLRSLKEISDGDVHISG
NKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGREG
VDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNT
LVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVR
KRTLRLQLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIK
ELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLL
NWCVQIAKGMNYLEDRLVHRDLAARNVLVKTQHVKITDFGLAKLLGAEKEYHAEGGKVPKWMALLES
ILHRIYTHQSDVWSYGVTWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDA
DSRPKFRELIIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADLEYLIPQQGFFS
SPSTSRTPLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDFTFLPVPGEWL
WKQSCSSTSTHSAAASLQCPSQVLPPASPEGETVADLQTQ

[0178]

EGFRvIII (del2-7 EGFR)

Nucleotide sequence (SEQ ID NO: 5)

```
ATGCGACCCTCCGGGACGG
CCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCCGGCAGTCGGGCTCTGGAGGAAAAGAAAGG
TAATTATGTGGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA
GACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATAGGTATTGGTG
AATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAACACTTCAAAAACTGCACCTCCATCAGTGG
CGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATACTCCTCCTCTGGATCCACAG
GAACTGGATATTCTGAAAACCGTAAAGGAAATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACA
GGACGGACCTCCATGCCTTTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTTC
TCTTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT
GTGATAATTTCAAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTGTTTGGGACCT
CCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCA
TGCTTGTGCTCCCCGAGGGCTGCTGGGGCCCGAGCCCAGGGACTGCGTCTCTTGCCGGAATGTCAGC
CGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTG
AGTGCATACAGTGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGA
CAACTGTATCCAGTGTGCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCCGCAGGAGTCATG
GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCCAACT
GCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGC
CACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTCATGCGAAGG
CGCCACATCGTTCGGAAGCGCACGCTGCGGAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACAC
CCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCTTGAAGGAACTGAATTCAAAAAGATCAAAGT
GCTGGGCTCCGGTTCGCTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTCGATGAAGCCT
ACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATCTGCCTCACCTCCACCGTGCA
GCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGACTATGTCCGGAACACAAAGACAATATTGGC
TCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGG
```

TGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGG
GCTGGCCAAACTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG
ATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTACGGGGTGACTG
TTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCT
GGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACCATCGATGTCTACATGATCATGGTCAAGTGC
TGGATGATAGACGCAGATAGTCGCCCCAAAGTTCCGTGAGTTGATCATCGAATTCTCCAAAATGCCCCGAG
ACCCCCAGCGCTACCTTGTCAATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACCT
CTACCGTGCCCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG
CAGGGCTTCTTCAGCAGCCCCCTCCACGTCACGGACTCCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACA
ATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCA
GCGATACAGCTCAGACCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCT
GAATACATAAACCAGTCCGTTCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGC
CTCTGAACCCCGCGCCAGCAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGA
GTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACATTTCGACAGCCCTGCCCACTGGGCCCAGAAA
GGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAA
ATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAATT
TATTGGAGCATGA

[0179]

Amino acid sequence (SEQ ID NO: 6)

MRPSGTAGAALLALLAALCPASRALEEKKNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVC
NGIGIGEFKDSLSINATNIKHFNCTISISGDLHILPVAFRGDSFHTTPPLDPQELDILKTVKEITGFLLI
QAWPENRTDLHAFENLEIIRGRKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINW
KKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPR
EFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVC
HLCHPNCTYGCTGPGLEGCPNTPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRLRLQERE
LVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANK
EILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNY

LEDRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEKEYHAEGGKVPIKWMALESILHRIYTHQSDV
WSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYIMVKCWMIDADSRPKFRELIIE
FSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADAYLIPQGGFFSSPSTSRTPLLSS
LSATSNNSTVACIDRNLQSCPIKEDSFLQRYSSDPTGALTEDSIDDFTLPVPEYINQSVPKRPAGSVQN
PVYHNPQLNPAPSRDPHYQDPHSTAVGNPEYLNTPQTCVNSTFDSAPAHWAQKGSHQISLDNPDYQQDF
PKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA

[0180]

In the present invention, "EGFR-positive tumor" is tumor in which the EGFR protein or the EGFR gene is detected. The EGFR protein and the EGFR gene also include mutant EGFR protein and mutant EGFR gene having a point mutation, an insertion mutation, or a deletion mutation, etc.

[0181]

Examples of the method for detecting the EGFR protein include usual detection methods commonly used, such as ELISA, Western blotting, and immunostaining using an antibody specifically binding to the EGFR protein. The antibody specifically binding to the EGFR protein may be a commercially available product or may be prepared by a usual method commonly used.

[0182]

Examples of the method for detecting the EGFR gene include usual detection methods commonly used, such as Northern blotting, Southern blotting, RT-PCR, real-time PCR, digital PCR, DNA microarrays, *in situ* hybridization, and sequence analysis. Another example thereof includes a detection method using cobas EGFR mutation detection kit (Roche Diagnostics K.K.), which is a commercially available EGFR gene mutation detection kit.

[0183]

In the present description, the term "effective amount" used regarding the pyrimidine compound of the present invention means the amount of the compound

of the present invention that induces the biological or medical response of a subject, such as, for example, reduction or inhibition of enzyme or protein activity; or ameliorates symptoms, alleviates conditions, and retards or delays the progression of disease; or prevents disease; etc. (therapeutically effective amount).

In the present description, the term "subject" includes mammals and non-mammals. Examples of the mammal may include, but are not limited to, a human, a chimpanzee, an ape, a monkey, a bovine, a horse, sheep, a goat, a swine, a rabbit, a dog, a cat, a rat, a mouse, a Guinea pig, a hedgehog, a kangaroo, a mole, a wild pig, a bear, a tiger, and a lion. Examples of the non-mammal may include, but are not limited to, birds, fish, and reptiles. In one embodiment, the subject is a human, and may be a human who has been diagnosed to need the treatment for the symptoms, conditions or disease disclosed in the present description.

[0184]

Upon the use of the compound of the present invention or a salt thereof as a medicament, a pharmaceutically acceptable carrier is mixed into it, as necessary, and various types of dosage forms can be adopted depending on the preventive or therapeutic purpose. Examples of the dosage form may include all of an oral agent, an injection, a suppository, an ointment, and a patch. Preferably, an oral agent is adopted. These dosage forms can be produced by commonly used production methods that are known to skilled persons.

[0185]

One embodiment of the present invention provides an antitumor agent for oral administration, comprising the compound of the present invention or a salt thereof as an active ingredient. In addition, one embodiment of the present invention provides a method for preventing and/or treating tumor, comprising administering an effective amount of the compound of the present invention or a salt thereof to a subject in need thereof by oral administration. Moreover, one

embodiment of the present invention provides use of the compound of the present invention or a salt thereof for the production of an antitumor agent for oral administration. Furthermore, one embodiment of the present invention provides the compound of the present invention or a salt thereof for use in the prevention and/or treatment of tumor by oral administration thereof.

[0186]

One embodiment of the present invention provides a pharmaceutical composition comprising the compound of the present invention or a salt thereof. The pharmaceutical composition according to one embodiment of the present invention comprises the compound of the present invention or a salt thereof, and a pharmaceutically acceptable carrier. Further, one embodiment of the present invention provides use of the compound of the present invention or a salt thereof for the production of a pharmaceutical composition. Another embodiment of the present invention provides the compound of the present invention or a salt thereof for use as a medicament.

[0187]

As pharmaceutically acceptable carriers, various types of organic or inorganic carrier substances, which are commonly used as preparation materials, are used. When the compound of the present invention is processed into a solid preparation, examples of the pharmaceutically acceptable carrier mixed into the compound of the present invention may include an excipient, a binder, a disintegrator, a lubricant, a coating agent, and a coloring agent. When the compound of the present invention is processed into a liquid preparation, examples of the pharmaceutically acceptable carrier mixed into the compound of the present invention may include a solvent, a solubilizer, a suspending agent, a tonicity agent, a buffer, and a soothing agent. In addition, preparation additives such as an

antiseptic, an antioxidant, a sweetener, and a stabilizer can also be used, as necessary.

[0188]

In the case of preparing a solid preparation for oral administration, an excipient, and as necessary, a binder, a disintegrator, a lubricant, a coloring agent, a corrigent, etc. are added to the pyrimidine compound of the present invention, and thereafter, a tablet, a coated tablet, a granule, a powder agent, a capsule, etc. can be produced according to ordinary methods.

[0189]

In the case of preparing an injection, a pH adjuster, a buffer, a stabilizer, a tonicity agent, a local anesthetic, etc. are added to the pyrimidine compound of the present invention, and thereafter, subcutaneous, intramuscular, and intravenous injections can be produced according to ordinary methods.

[0190]

The amount of the compound of the present invention to be mixed into the above-described each dosage unit form depends on the symptoms of a subject to whom the present pyrimidine compound should be applied, the dosage form and the like, and thus, the amount of the compound of the present invention is not constant. In general, it is preferable that the applied dose is set to be 0.05 to 1000 mg per dosage unit form in the case of an oral agent, it is set to be 0.01 to 500 mg per dosage unit form in the case of an injection, and it is set to be 1 to 1000 mg per dosage unit form in the case of a suppository.

The daily dose of a drug having the above-described dosage form is different depending on the symptoms, body weight, age, sex and the like of a subject, and thus, it cannot be generally determined. However, the compound of the present invention may be administered to an adult (body weight: 50 kg) at a daily dose of generally 0.05 to 5000 mg, and preferably 0.1 to 1000 mg.

[0191]

The malignant tumor that is the target of the present invention is not particularly limited. Examples of the tumor may include brain tumor, head and neck cancer, digestive cancer (esophageal cancer, stomach cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder and/or bile duct cancer, etc.), pancreatic cancer, colorectal cancer (colon cancer, rectal cancer, etc.), etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer, uterine cancer (cervical cancer, endometrial cancer, etc.), etc.), urinary organ cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumor, etc.), hematopoietic tumor (leukemia, malignant lymphoma, multiple myeloma, etc.), bone and/or soft tissue tumor, and skin cancer. Among these, preferable is lung cancer, breast cancer, stomach cancer, head and neck cancer, brain tumor, colorectal cancer, bladder cancer, biliary tract cancer or uterine cancer, and more preferable is lung cancer, breast cancer, colorectal cancer, or brain tumor.

[0192]

In one embodiment, the tumor that is the target of the present invention is a malignant tumor having EGFR overexpression, EGFR gene amplification, or EGFR mutation. Specific examples of the tumor may include brain tumor, head and neck cancer, digestive cancer (esophageal cancer, stomach cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder and/or bile duct cancer, etc.), pancreatic cancer, colorectal cancer (colon cancer, rectal cancer, etc.), etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer, uterine cancer (cervical cancer, endometrial cancer, etc.), etc.), urinary organ cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumor, etc.), hematopoietic tumor (leukemia, malignant lymphoma, multiple myeloma, etc.), bone and/or soft tissue tumor, and skin cancer.

Among these, preferable is lung cancer, breast cancer, stomach cancer, head and neck cancer, brain tumor, colorectal cancer, bladder cancer, biliary tract cancer or uterine cancer, and more preferable is lung cancer, breast cancer, colorectal cancer, or brain tumor.

[0193]

In one embodiment, the tumor that is the target of the present invention is an EGFR positive tumor. Specific examples of the tumor may include brain tumor, head and neck cancer, digestive cancer (esophageal cancer, stomach cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder and/or bile duct cancer, etc.), pancreatic cancer, colorectal cancer (colon cancer, rectal cancer, etc.), etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer, uterine cancer (cervical cancer, endometrial cancer, etc.), etc.), urinary organ cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumor, etc.), hematopoietic tumor (leukemia, malignant lymphoma, multiple myeloma, etc.), bone and/or soft tissue tumor, and skin cancer. Among these, preferable is lung cancer, breast cancer, stomach cancer, head and neck cancer, brain tumor, colorectal cancer, bladder cancer, biliary tract cancer or uterine cancer, and more preferable is lung cancer, breast cancer, colorectal cancer, or brain tumor.

[0194]

In one embodiment, the tumor is a brain tumor. The pyrimidine compound of the present invention may be useful for the treatment of the symptoms of brain that is required to pass through the blood-brain barrier. The pyrimidine compound of one embodiment has favorable permeability through the blood-brain barrier for the delivery thereof into the brain, namely, excellent brain penetration properties. As an indicator of the penetration properties of the compound into the

brain, the concentration of the compound in the brain or a K_p value (brain-to-plasma drug concentration ratio) is applied.

[0195]

The brain tumor treated with the pyrimidine compound of the present invention includes metastatic brain tumor and primary brain tumor.

[0196]

Examples of the brain tumor may include, but are not particularly limited to, metastatic brain tumor (e.g., brain metastasis of lung cancer, breast cancer, stomach cancer, colorectal cancer, bladder cancer, biliary tract cancer, uterine cancer, etc. (preferably, lung cancer, breast cancer, or stomach cancer)), pilocytic astrocytoma, diffuse astrocytoma, oligodendroma and/or oligodendroastrocytoma, anaplastic astrocytoma and/or anaplastic oligodendroglioma, anaplastic oligodendroastrocytoma, glioblastoma, ependymoma, anaplastic ependymoma, ganglioglioma, central neurocytoma, medulloblastoma, germinoma, central nervous system malignant lymphoma, meningioma, neurilemmoma, GH secreting pituitary adenoma, PRL-secreting pituitary adenoma, ACTH-secreting pituitary adenoma, nonfunctional pituitary adenoma, craniopharyngioma, chordoma, hemangioblastoma, and epidermoid tumor.

EXAMPLES

[0197]

Hereinafter, the present invention will be described in detail in the following examples. However, these examples are not intended to limit the scope of the present invention.

[0198]

In the present description, "room temperature" generally means a temperature that is from approximately 10°C to approximately 35°C. In addition,

in the following Examples regarding compounds, "%" indicates weight percent, unless otherwise specified.

[0199]

Various types of reagents used in the Examples were commercially available products, unless otherwise specified. Silica gel chromatography was carried out using Biotage SNAP Cartridge Ultra, manufactured by Biotage Japan Ltd. Basic silica gel chromatography was carried out using Biotage SNAP Cartridge Isolute Flash-NH₂, manufactured by Biotage Japan Ltd.

[0200]

Preparative thin-layer chromatography was carried out using Kieselgel TM60F254, Art. 5744, manufactured by Merck, or NH₂ Silica Gel 60F254 Plate-Wako, manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.

¹H-NMR was measured using tetramethylsilane as a reference material, and employing AL400 (400 MHz) manufactured by JEOL, Mercury (400 MHz) manufactured by Varian, or Inova (400 MHz) manufactured by Varian. Moreover, mass spectrum was measured using Micromass ZQ or SQD manufactured by Waters, according to electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). Microwave reaction was carried out using Initiator manufactured by Biotage Japan Ltd.

[0201]

Abbreviations have the following meanings.

s: Singlet

d: Doublet

t: Triplet

q: Quartet

dd: Double doublet

dt: Double triplet

td: Triple doublet

tt: Triple triplet

ddd: Double double doublet

ddt: Double double triplet

dtd: Double triple doublet

tdd: Triple double doublet

m: Multiplet

br: Broad

ATP: Adenosine triphosphate

DMSO-d₆: Deuterated dimethyl sulfoxide

CDCl₃: Deuterated chloroform

EDTA: Ethylenediaminetetraacetic acid

THF: Tetrahydrofuran

DMF: N,N-dimethylformamide

DMSO: Dimethyl sulfoxide

NMP: N-methyl pyrrolidone

HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium

hexafluorophosphate

HPMC: Hypromellose

PdCl₂(PPh₃)₂: Dichlorobis(triphenylphosphine)palladium(II)

[0202]

< Reference Example 1 >

Reference Example 1(1)

tert-Butyl (2S,4R)-4-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylpyrrolidine-1-carboxylate

tert-Butyl (2S,4S)-4-hydroxy-2-methylpyrrolidine-1-carboxylate (19.0 g)
and 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (13.1 g) were dissolved in THF

(190 mL), and the obtained solution was then cooled to 0°C. Thereafter, triphenylphosphine (37.2 g) and diisopropyl azodicarboxylate (28.1 mL) were added to the reaction solution, and the temperature of the mixture was then increased to room temperature, followed by stirring for 1 hour. Thereafter, the reaction mixture was concentrated under reduced pressure, and the obtained residue was then purified by silica gel chromatography (hexane : ethyl acetate) to obtain the corresponding coupling body. The obtained compound was used in the subsequent reaction without being further purified.

[0203]

The obtained coupling body, THF (114 mL) and ammonia water (114 mL) were added into a pressure resistant tube, and the obtained mixture was then stirred at 100°C for 14 hours. Thereafter, the reaction mixture was cooled to room temperature, and was then poured into water (285 mL). The thus obtained mixture was stirred at room temperature for 5 hours. Thereafter, the precipitated solid was collected by filtration, was then washed with water, and was then dried to obtain a product of interest (34.5 g).

¹HNMR (CDCl₃)δ: 8.27(s,1H) 7.15(s,1H) 5.55-5.73(m,2H) 5.12-5.25(m,1H) 3.86-4.18(m,2H) 3.43-3.57(m,1H) 2.59-2.69(m,1H) 1.92-2.03(m,1H) 1.48(s,9H) 1.30-1.40(m,3H)

ESI-MS m/z 444 (MH⁺)

[0204]

Reference Example 1(2)

4-Amino-7-((3R,5S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid

The compound of Reference Example 1(1) (28.0 g), 10% palladium carbon catalyst (720 mg), NMP (84 mL), methanol (26 mL), and triethylamine (17.6 mL) were added into a pressure resistant tube, followed by carbon monoxide

substitution, and the obtained mixture was stirred at 100°C for 2 hours. Thereafter, the reaction mixture was cooled to room temperature, a 2 M sodium hydroxide aqueous solution (79 mL) was then added thereto, and the obtained mixture was then stirred at 80°C for 2 hours. Thereafter, the reaction mixture was cooled to room temperature, was then filtrated through Celite, and was then washed with methanol. Subsequently, methanol in the filtrate was concentrated under reduced pressure. Water was further added, and the water layer was then washed with tert-butyl methyl ether. A 1 M potassium hydrogen sulfate aqueous solution was added to the water layer to adjust the pH to approximately 3. The precipitated solid was collected by filtration, was then washed with water, and was then dried to obtain a product of interest (23.4 g).

¹HNMR (400MHz, DMSO-d₆)δ: 8.14 (s, 1H) 8.08 (s, 1H) 5.16-4.93(m,1H) 4.07-3.79(m,2H) 3.61-3.45(m,1H) 2.53(m,1H) 2.33-2.02(m,1H) 1.42(s,9H) 1.29(d,J = 6.1Hz,3H) ESI-MS m/z 362 (MH⁺)

[0205]

< Examples >

Example 1(1)

tert-Butyl-4-amino-6-bromo-7-((3R,5S)-1-(tert-butoxycarbonyl)-5-methylpyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate

Under a nitrogen atmosphere, the compound of Reference Example 1(2) (15.0 g) was dissolved in chloroform (150 mL), and 2-tert-butyl-1,3-diisopropylisourea (25 mL) was then added to the above obtained solution. The temperature of the obtained mixture was increased to 60°C, and the mixture was then stirred for 2 hours. Thereafter, 2-tert-butyl-1,3-diisopropylisourea (25 mL) was further added to the reaction mixture, and the thus obtained mixture was then stirred for 2 hours. Thereafter, the reaction mixture was cooled to room temperature, and was then concentrated under reduced pressure. To the obtained

residue, tert-butyl methyl ether was added, and the precipitated solid was collected by filtration and was then washed with tert-butyl methyl ether. The filtrate was concentrated under reduced pressure, and tert-butyl methyl ether was then added to the obtained residue. The precipitated solid was collected by filtration, and was then washed with tert-butyl methyl ether. The obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a tert-butyl ester form. The obtained compound was used in the subsequent halogenation reaction without being further purified.

[0206]

The obtained tert-butyl ester form was dissolved in chloroform (140 mL), and N-bromosuccinimide (11.8 g) was then added to the above obtained solution. The obtained mixture was stirred at room temperature for 24 hours. Thereafter, to the reaction mixture, chloroform and 10% sodium bisulfite aqueous solution were successively added, and the obtained mixture was then extracted with chloroform. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a product of interest (13.8 g).

¹HNMR (CDCl₃)δ: 8.02 (s, 1H) 5.74-5.13(m,2H) 4.07-3.64(m,2H) 2.43-2.29(m,1H) 2.07-1.97(m,1H) 1.63(s,9H) 1.48(m,12H)

ESI-MS m/z 496,498 (MH⁺)

[0207]

Example 1(2)

tert-Butyl-7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-bromo-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate

The compound of Example 1(1) (11.4 g) was dissolved in THF (57 mL), and the obtained solution was then cooled to 0°C. Thereafter, 4 M hydrogen

chloride in 1,4-dioxane solution (114 mL) was added to the mixture, and the thus obtained mixture was then stirred at 0°C for 10 hours. Subsequently, to the reaction mixture, a 5 M sodium hydroxide aqueous solution (92 mL), acetonitrile (57 mL), diisopropylethylamine (20 mL), and acryloyl chloride (2.0 mL) were added, and the obtained mixture was then stirred for 30 minutes. Thereafter, the reaction mixture was extracted with ethyl acetate, and the gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain a product of interest (7.72 g).

¹HNMR (CDCl₃)δ: 8.26-8.16(m,1H) 6.62-6.30(m,2H) 5.81-5.64(m,1H) 5.33-5.14(m,1H) 4.81-3.75(m,3H) 3.07-2.86(m,1H) 2.67-2.33(m,1H) 1.69-1.61(m,9H) 1.60-1.51(m,3H)

ESI-MS m/z 450,452 (MH⁺)

[0208]

Example 1(3)

tert-Butyl-7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate

1.0 M Propyne in DMF solution (85.7 mL) was added to the compound of Example 1(2) (7.72 g), acetonitrile (154 mL), triethylamine (7.2 mL), PdCl₂(PPh₃)₂ (1.2 g), and copper(I) iodide (330 mg), followed by nitrogen substitution.

Thereafter, the mixture was stirred at 70°C for 4 hours. Thereafter, the reaction mixture was cooled to room temperature, and ethyl acetate and a saturated sodium hydrogen carbonate aqueous solution were added to the mixture. Thereafter, the obtained mixture was extracted with ethyl acetate, and the gathered organic layer was washed with water, and then with saturated saline. The resultant was dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure.

The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain a product of interest (4.06 g).

¹HNMR (CDCl₃)δ: 8.29-8.17(m,1H) 6.63-6.30(m,2H) 5.81-5.63(m,1H) 5.42-5.15(m,1H) 4.66-3.81(m,3H) 3.01-2.82(m,1H) 2.65-2.32(m,1H) 2.92-2.13(m,3H) 1.65-1.59(m,9H) 1.57-1.49(m,3H)

ESI-MS m/z 410 (MH⁺)

[0209]

Example 1(4)

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-carboxylic acid

The compound of Example 1(3) (1.52 g) was dissolved in chloroform (5 mL), and trifluoroacetic acid (5 mL) was then added to the above obtained solution. The mixture was stirred at room temperature for 2 hours, and the reaction mixture was then concentrated under reduced pressure. To the residue, chloroform was added, and the obtained mixture was concentrated under reduced pressure again. The residue was dried under reduced pressure to obtain a product of interest (1.25 g).

ESI-MS m/z 354 (MH⁺)

[0210]

Example 1(5)

7-(R)-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-(3,5-difluorophenyl)ethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

To the compound of Example 1(4) (100 mg) in DMF (1.0 mL) solution, (R)-1-(3,5-difluorophenyl)ethan-1-amine (89.0 mg), diisopropylethylamine (0.25 mL), and HATU (215 mg) were added, and the obtained mixture was then stirred at room temperature for 2 hours. Thereafter, to the reaction mixture, a saturated sodium hydrogen carbonate aqueous solution was added, and the obtained mixture

was then extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain the title compound (60 mg).

¹HNMR (DMSO-d₆)δ: 8.51(d, *J* = 7.3Hz, 1H) 8.16 (s, 1H) 7.25-7.07(m, 3H) 6.74-6.47(m, 1H) 6.25-6.08(m, 1H) 5.78-5.58(m, 1H) 5.41-5.21(m, 1H) 5.21-5.06(m, 1H) 4.45-4.29(m, 1H) 4.24-3.91(m, 2H) 2.78-2.58(m, 1H) 2.52-2.41(m, 1H) 2.23(s, 3H) 1.48(d, *J* = 7.1Hz, 3H) 1.39(d, *J* = 6.1Hz, 3H)

ESI-MS *m/z* 493 (MH⁺)

[0211]

Example 2

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that (R)-1-phenylethan-1-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (DMSO-d₆)δ: 8.35(d, *J* = 7.8Hz, 1H) 8.17-8.13(m, 1H) 7.48-7.23(m, 5H) 6.76-6.46(m, 1H) 6.28-6.06(m, 1H) 5.81-5.58(m, 1H) 5.43-5.02(m, 2H) 4.42-4.28(m, 1H) 4.21-3.96(m, 2H) 2.74-2.59(m, 1H) 2.54-2.41(m, 1H) 2.17(s, 3H) 1.50(d, *J* = 6.8Hz, 3H) 1.42-1.33(m, 3H)

ESI-MS *m/z* 457 (MH⁺)

[0212]

Example 3

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-phenylpropan-2-yl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that 2-phenylpropan-2-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (DMSO-d₆)δ: 8.26(s,1H) 8.16-8.08(m,1H) 7.44(dd,*J* = 8.8,1.2Hz,2H) 7.38-7.28(m,2H) 7.21(tt,*J* = 7.3,1.27Hz,1H) 6.76-6.50(m,1H) 6.25-6.10(m,1H) 5.79-5.62(m,1H) 5.45-5.19(m,1H) 4.45-4.30(m,1H) 4.26-4.01(m,2H) 2.79-2.42(m,2H) 2.29-2.22(m,3H) 1.71(s,6H) 1.43-1.36(m,3H)

ESI-MS *m/z* 471 (MH⁺)

[0213]

Example 4

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylpropyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that (R)-1-phenylpropan-1-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (DMSO-d₆)δ: 8.35(brd,*J* = 8.0Hz,1H) 8.17-8.11(m,1H) 7.46-7.22(m,5H) 6.74-6.50(m,1H) 6.26-6.08(m,1H) 5.79-5.60(m,1H) 5.40-5.21(m,1H) 4.99-4.87(m,1H) 4.43-4.30(m,1H) 4.23-3.94(m,2H) 2.76-2.42(m,2H) 2.21(s,3H) 1.95-1.74(m,2H) 1.44-1.34(m,3H) 0.91(t,*J* = 7.3Hz,3H)

ESI-MS *m/z* 471 (MH⁺)

[0214]

Example 5

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-(2-fluorophenyl)propan-2-yl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that 2-(2-fluorophenyl)propan-2-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.28(s,1H) 8.11(d,J = 4.4Hz,1H) 8.02(s,1H) 7.47-7.42(m,1H) 7.29-7.23(m,1H) 7.15(t,J = 7.7Hz,1H) 7.02(ddd,J = 12.5,8.1,1.1Hz,1H) 6.58-6.35(m,2H) 5.79-5.70(m,1H) 5.30-5.19(m,1H) 4.53(t,J = 10.1Hz,0.7H) 4.38-4.25(m,1.6H) 3.92(t,J = 8.8Hz,0.7H) 2.91-2.78(m,1H) 2.70-2.60(m,0.3H) 2.54-2.43(m,0.7H) 2.28(d,J = 7.0Hz,3H) 1.88(dt,J = 10.0,5.0Hz,6H) 1.53(t,J = 6.2Hz,3H)
ESI-MS m/z 489 (MH⁺)

[0215]

Example 6

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-(3-chlorophenyl)ethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that (R)-(+)-1-(3-chlorophenyl)ethylamine hydrochloride was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.22(d,J = 5.9Hz,1H) 7.75(d,J = 7.0Hz,1H) 7.38(s,1H) 7.35-7.27(m,3H) 6.58-6.33(m,2H) 5.78-5.66(m,1H) 5.29-5.19(m,2H) 4.56(t,J = 10.3Hz,0.7H) 4.39-4.20(m,1.6H) 3.89(t,J = 8.8Hz,0.7H) 2.94-2.82(m,1H) 2.66-2.58(m,0.3H) 2.46(dt,J = 14.5,6.1Hz,0.7H) 2.18(d,J = 11.0Hz,3H) 1.60(d,J = 7.0Hz,3H) 1.55-1.51(m,3H)

ESI-MS m/z 491,493 (MH⁺)

[0216]

Example 7

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-(2,4-difluorophenyl)ethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that (R)-(+)-1-(2,4-difluorophenyl)ethylamine hydrochloride was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.20(d, *J* = 5.9Hz, 1H) 7.98(d, *J* = 7.7Hz, 1H) 7.37-7.31(m, 1H) 6.90-6.81(m, 2H) 6.58-6.35(m, 2H) 5.78-5.65(m, 1H) 5.44-5.37(m, 1H) 5.30-5.19(m, 1H) 4.56(t, *J* = 10.1Hz, 0.7H) 4.38-4.23(m, 1.6H) 3.88(t, *J* = 8.8Hz, 0.7H) 2.94-2.83(m, 1H) 2.66-2.57(m, 0.3H) 2.51-2.42(m, 0.7H) 2.27(d, *J* = 9.2Hz, 3H) 1.61(d, *J* = 7.0Hz, 3H) 1.56-1.51(m, 3H)

ESI-MS *m/z* 493 (MH⁺)

[0217]

Example 8

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(prop-1-yn-1-yl)-N-((S)-2,2,2-trifluoro-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that (S)-2,2,2-trifluoro-1-phenylethan-1-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.40(d, *J* = 8.8Hz, 1H) 8.16(s, 1H) 7.44(s, 5H) 6.58-6.38(m, 2H) 5.92-5.84(m, 1H) 5.81-5.69(m, 1H) 5.29-5.19(m, 1H) 4.55(t, *J* = 10.3Hz, 0.7H) 4.41-4.24(m, 1.6H) 3.91(t, *J* = 8.6Hz, 0.7H) 2.92-2.80(m, 1H) 2.70-2.61(m, 0.3H) 2.54-2.46(m, 0.7H) 2.35(d, *J* = 8.4Hz, 3H) 1.54(t, *J* = 7.3Hz, 3H)

ESI-MS *m/z* 511 (MH⁺)

[0218]

Example 9

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-(2-phenylpropan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exceptions that cyclopropylacetylene was used instead of 1.0 M propyne in DMF solution in Example 1(3), and that 2-phenylpropan-2-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.15(s,1H) 8.00(s,1H) 7.44(d,*J* = 7.7Hz,2H) 7.37(t,*J* = 7.7Hz,2H) 7.32-7.27(m, 1H) 6.66-6.30(m,2H) 5.81-5.69(m,1H) 5.38-5.24(m,1H) 4.48(t,*J* = 9.9Hz,0.7H) 4.42-4.29(m,1.6H) 4.22(t,*J* = 10.4Hz,0.7H) 2.77-2.68(m,1H) 2.67-2.60(m,0.3H) 2.59-2.52(m,0.7H) 1.83(s,6H) 1.60-1.52(m,4H) 1.08-1.01(m,2H) 0.92-0.88(m,2H)

ESI-MS *m/z* 497 (MH⁺)

[0219]

Example 10

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-(2,3-difluorophenyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exceptions that cyclopropylacetylene was used instead of 1.0 M propyne in DMF solution in Example 1(3), and that (R)-(+)-1-(2,3-difluorophenyl)ethylamine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.17(d,*J* = 4.0Hz,1H) 8.04(d,*J* = 8.1Hz,1H) 7.15-7.05(m,3H) 6.58-6.36(m,2H) 5.80-5.68(m,1H) 5.49-5.42(m,1H) 5.34-5.24(m,1H) 4.52(t,*J* = 10.1Hz,0.7H) 4.37-4.23(m,1.6H) 3.92(t,*J* = 8.8Hz,0.7H) 2.86-2.76(m,1H) 2.69-2.63(m,0.3H) 2.52-2.46(m,0.7H) 1.73-1.63(m,4H) 1.55(t,*J* = 5.3Hz,3H) 1.14-1.07(m,2H) 1.01-0.92(m,2H)

ESI-MS *m/z* 519 (MH⁺)

[0220]

Example 11

Example 11(1)

tert-Butyl(2S,4R)-4-(4-amino-6-bromo-5-(((R)-1-phenylethyl)carbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylpyrrolidine-1-carboxylate

The compound of Reference Example 1(2) (1.00 g), (R)-(+)-1-phenylethylamine (0.503 g), diisopropylethylamine (1.79 g), and N,N-dimethylformamide (10 mL) were added, and subsequently, HATU (1.58 g) was added. The obtained mixture was stirred at room temperature overnight. Thereafter, to the reaction mixture, ethyl acetate and a saturated sodium hydrogen carbonate aqueous solution were added, and the obtained mixture was then extracted with ethyl acetate. The gathered organic layer was washed with water, and then with saturated saline. The resultant was dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain an amide form (1.53 g). The obtained compound was used in the subsequent reaction without being further purified.

To the amide form (1.53 g), chloroform (15 mL) was added, and the obtained mixture was then cooled to 0°C. Thereafter, N-bromosuccinimide (0.88 g) was added to the reaction mixture, and the obtained mixture was then stirred at 0°C for 1 hour. Thereafter, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a product of interest (1.39 g).

¹HNMR (CDCl₃)δ: 8.21 (s, 1H) 7.42-7.28(m,5H) 6.97(d,*J* = 7.3Hz,1H) 5.36-5.29(m,1H) 5.20-5.07(m,1H) 4.30(t,*J* = 10.3Hz,1H) 4.04-3.72(m,2H) 3.00-2.86(m,1H) 2.38(dt,*J* = 14.3,6.0Hz,1H) 1.63(d,*J* = 7.0Hz,3H) 1.53-1.43(m,12H)
ESI-MS *m/z* 543,545 (MH⁺)

[0221]

Example 11(2)

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-bromo-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

To the compound of Example 11(1) (600 mg), chloroform (3 mL) was added, and the obtained mixture was then cooled to 0°C. Thereafter, trifluoroacetic acid (4.44 g) was added to the reaction mixture, and the thus obtained mixture was then stirred at room temperature for 1 hour. Thereafter, the reaction mixture was concentrated under reduced pressure, and acetonitrile (5 mL) was then added to the residue. The obtained mixture was concentrated under reduced pressure again to obtain an amine form. The obtained compound was used in the subsequent reaction without being further purified.

To the obtained amine form, acetonitrile (3 mL) was added, and the obtained mixture was then cooled to 0°C. Thereafter, acryloyl chloride (99.9 mg) and diisopropylethylamine (713 mg) were added, and the obtained mixture was then stirred at 0°C for 1 hour. Thereafter, the reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel

chromatography (ethyl acetate : methanol) to obtain a product of interest (281 mg).

¹HNMR (CDCl₃)δ: 8.20(d, *J* = 7.3 Hz, 1H) 7.42-7.36(m, 4H) 7.32-7.28(m, 1H) 7.00-6.94(m, 1H) 6.57-6.33(m, 2H) 5.76-5.66(m, 1H) 5.36-5.29(m, 1H) 5.14-5.08(m, 1H) 4.71(t, *J* = 9.9 Hz, 0.7H) 4.42-4.23(m, 1.6H) 3.83(t, *J* = 8.6 Hz, 0.7H) 3.03-2.92(m, 1H) 2.60-2.57(m, 0.3H) 2.44-2.40(m, 0.7H) 1.64(d, *J* = 6.6 Hz, 3H) 1.56(dd, *J* = 11.7, 6.2 Hz, 3H)

ESI-MS *m/z* 497, 499 (MH⁺)

[0222]

Example 11(3)

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The compound of Example 11(2) (65 mg), dichlorobis(triphenylphosphine)dipalladium (9.2 mg), copper(I) iodide (5.0 mg), cyclopropylacetylene (13.0 mg), triethylamine (39.7 mg), and N,N-dimethylformamide (1.3 mL) were added, and the inside of the reaction system was then substituted with nitrogen. After that, the mixture was stirred at 70°C for 2.5 hours. Thereafter, to the reaction mixture, ethyl acetate and a saturated ammonium chloride aqueous solution were added, and the obtained mixture was then extracted with ethyl acetate. The gathered organic layer was washed with water, and then with saturated saline. The resultant was dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (chloroform : methanol) to obtain a product of interest (50 mg).

¹HNMR (CDCl₃)δ: 8.22(d, *J* = 5.1Hz, 1H) 7.82(d, *J* = 7.3Hz, 1H) 7.43-7.35(m, 4H) 7.30(t, *J* = 6.8Hz, 1H) 6.58-6.34(m, 2H) 5.77-5.66(m, 1H) 5.35-5.20(m, 2H) 4.54(t, *J* = 10.1Hz, 0.7H) 4.35-4.25(m, 1.6H) 3.88(t, *J* = 8.8Hz, 0.7H) 2.90-2.78(m, 1H) 2.65-2.56(m, 0.3H) 2.49-2.40(m, 0.7H) 1.63(d, *J* = 7.0Hz, 3H) 1.56-1.45(m, 4H) 1.03-0.91(m, 2H) 0.84-0.69(m, 2H)

ESI-MS *m/z* 483 (MH⁺)

[0223]

Example 12

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3,3-dimethylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 11, with the exception that 3,3-dimethyl-1-butyne was used instead of cyclopropylacetylene in Example 11(3).

¹HNMR (CDCl₃)δ: 8.22(d, *J* = 5.9Hz, 1H) 7.75(d, *J* = 7.7Hz, 1H) 7.38(dt, *J* = 15.5, 7.1Hz, 4H) 7.31-7.25(m, 1H) 6.57-6.34(m, 2H) 5.77-5.65(m, 1H) 5.44-

5.35(m,1H) 5.33-5.15(m,1H) 4.63(t, J = 10.1Hz,0.7H) 4.40-4.20(m,1.6H) 3.89(t, J = 8.8Hz,0.7H) 2.90-2.76(m,1H) 2.65-2.55(m,0.3H) 2.49-2.40(m,0.7H) 1.85(s,1H) 1.64(d, J = 7.0Hz,3H) 1.55(d, J = 5.9Hz,3H) 1.26(s,9H)

ESI-MS m/z 499 (MH⁺)

[0224]

Example 13

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3-methoxy-3-methylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 11, with the exception that 3-methoxy-3-methyl-1-butyne was used instead of cyclopropylacetylene in Example 11(3).

¹HNMR (CDCl₃) δ : 8.17 (s, 1H) 7.61(d, J = 7.7Hz,1H) 7.43-7.35(m,4H) 7.30(d, J = 7.0Hz,1H) 6.57-6.33(m,2H) 5.81-5.68(m,1H) 5.43-5.33(m,1H) 5.29-5.12(m,1H) 4.59(t, J = 10.1Hz,0.7H) 4.38-4.22(m,1.6H) 3.92(t, J = 8.6Hz,0.7H) 3.30(s,3H) 2.86-2.72(m,1H) 2.70-2.60(m,1.3H) 2.52-2.44(m,0.7H) 1.64(d, J = 7.0Hz,3H) 1.55(t, J = 5.5Hz,3H) 1.46(d, J = 2.2Hz,6H)

ESI-MS m/z 515 (MH⁺)

[0225]

Example 14

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(but-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 11, with the exception that 1-trimethylsilyl-1-butyne and tetra-n-butylammonium fluoride were used instead of cyclopropylacetylene in Example 11(3).

¹HNMR (CDCl₃) δ : 8.26-8.25(m,1H) 7.79(d, J = 7.3Hz,1H) 7.42-7.36(m,4H) 7.32-7.30(m,1H) 6.57-6.37(m,2H) 5.76-5.66(m,1H) 5.33-5.20(m,2H) 4.57(t, J =

10.3Hz,0.7H) 4.36-4.22(m,1.6H) 3.88(t, J = 8.8Hz,0.7H) 2.92-2.81(m,1H) 2.65-2.57(m,0.3H) 2.48-2.38(m,2.7H) 1.63(d, J = 7.0Hz,3H) 1.54-1.51(m,3H) 1.17-1.12(m,3H)

ESI-MS m/z 471 (MH⁺)

[0226]

Example 15

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-(2-fluorophenyl)propan-2-yl)-6-(3-methylbut-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 11, with the exceptions that 2-(2-fluorophenyl)propan-2-amine was used instead of (R)-(+)-1-phenylethylamine in Example 11(1), and that 3-methyl-1-butyne was used instead of cyclopropylacetylene in Example 11(3).

¹HNMR (CDCl₃) δ : 7.92 (s, 1H) 7.44(t, J = 7.9Hz,1H) 7.30-7.23(m,1H) 7.14(t, J = 7.5Hz,1H) 7.02(dd, J = 12.6,8.2Hz,1H) 6.58-6.35(m,2H) 5.80-5.69(m,1H) 5.33-5.16(m,1H) 4.58(t, J = 9.9Hz,0.7H) 4.38-4.23(m,1.6H) 3.91(t, J = 8.4Hz,0.7H) 3.03-2.93(m,1H) 2.89-2.75(m,1H) 2.69-2.60(m,0.3H) 2.53-2.43(m,0.7H) 1.88(s,6H) 1.55(d, J = 5.1Hz,3H) 1.36(d, J = 6.6Hz,6H)

ESI-MS m/z 517 (MH⁺)

[0227]

Example 16

Example 16(1)

tert-Butyl (2R,4S)-4-(benzyloxy)-2-((tosyloxy)methyl)pyrrolidine-1-carboxylate

tert-Butyl (2R,4S)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (2.0 g) was dissolved in methylene chloride (20 mL), and the obtained solution was then cooled to 0°C. Thereafter, 1,4-diazabicyclo[2.2.2]octane (2.2 g) and tosylate chloride (1.9 g) were added to the reaction solution, and the temperature

of the mixture was then increased to room temperature. The mixture was stirred for 4 hours. Thereafter, a saturated sodium hydrogen carbonate aqueous solution was added to the reaction mixture, and the obtained mixture was then extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a product of interest (4.32 g).

^1H NMR (CDCl_3) δ : 7.78(d, $J = 8.1\text{Hz}$, 2H), 7.42-7.29(m, 7H), 4.57-4.41(m, 2H), 4.39-3.96(m, 4H), 3.61-3.20(m, 2H), 2.46(s, 3H), 2.27-2.02(m, 2H), 1.48-1.31(m, 9H)

ESI-MS m/z 462 (MH^+)

[0228]

Example 16(2)

tert-Butyl (2S,4S)-4-(benzyloxy)-2-ethylpyrrolidine-1-carboxylate

Under a nitrogen atmosphere, copper iodide (2.04 g) was suspended in diethyl ether (12 mL), and the obtained suspension was then cooled to 0°C . Thereafter, 1.04 M methyl lithium in diethyl ether solution (0.36 mL) was added, and the obtained mixture was then stirred at 0°C for 30 minutes. Subsequently, the compound of Example 16(1) (1.98 g) in methylene chloride (4.0 mL) solution was added to the reaction mixture, and the temperature of the obtained mixture was then increased to room temperature. The mixture was stirred for 1 hour. Thereafter, the reaction mixture was cooled to 0°C , and a saturated ammonium chloride aqueous solution was then added to the reaction mixture. The thus obtained mixture was extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a product of interest (707 mg).

¹HNMR (CDCl₃)δ 7.42-7.25(m,5H), 4.66-4.40(m,2H), 4.17-4.03(m,1H), 4.00-3.26(m,3H), 2.24-2.09(m,1H), 1.96-1.71(m,2H), 1.48(s,9H), 1.45- 1.31(m,1H), 0.86(t, J = 7.4Hz, 3H)

ESI-MS m/z 306 (MH⁺)

[0229]

Example 16(3)

tert-Butyl (2S,4S)-2-ethyl-4-hydroxypyrrolidine-1-carboxylate

The compound of Example 16(2) (1.06 g) and a 10% palladium hydroxide carbon catalyst (160 mg) were suspended in ethanol (11 mL) and THF (11 mL), followed by hydrogen substitution, and the resultant was then stirred at room temperature for 20 hours. Thereafter, the reaction mixture was filtrated through Celite, and was then washed with ethanol, and the filtrate was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a product of interest (709 mg).

¹HNMR (CDCl₃)δ 4.46-4.36(m,1H), 4.02-3.81(m,1H), 3.71-3.35(m,2H), 2.15-1.99(m,1H), 1.95-1.72(m,2H), 1.49(s,9H), 1.46-1.35(m,1H), 0.86(t, J = 7.5Hz, 3H)

ESI-MS m/z 216 (MH⁺)

[0230]

Example 16(4)

tert-Butyl (2S,4R)-4-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-ethylpyrrolidine-1-carboxylate

The compound of Example 16(3) (709 mg) and 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1.11 g) were dissolved in THF (7.1 mL), and the obtained solution was then cooled to 0°C. Thereafter, triphenylphosphine (1.3 g) and diisopropyl azodicarboxylate (1.00 mL) were added, and the temperature of the obtained mixture was then increased to room temperature, followed by stirring the mixture for 1 hour. Thereafter, the reaction mixture was concentrated under

reduced pressure, and the obtained residue was then purified by silica gel chromatography (hexane : ethyl acetate) to obtain the corresponding coupling body. The obtained compound was used in the subsequent reaction without being further purified. Into a pressure resistant tube, the obtained coupling body, THF (5.4 mL), and ammonia water (5.4 mL) were added, and the obtained mixture was then stirred at 100°C for 14 hours. Thereafter, the reaction mixture was cooled to room temperature, and was then poured into water (12.8 mL), and the mixed solution was then extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain a product of interest (797 mg).
¹HNMR (CDCl₃) δ 8.29(s,1H), 7.14(s,1H), 5.67(br s,2H), 5.32-5.09(m,1H), 4.24-4.08(m,1H), 3.95-3.79(m,1H), 3.46(dd,J = 9.3,11.0Hz,1H), 2.70-2.55(m,1H), 2.06-1.95(m,1H), 1.59-1.51(m,2H), 1.49(s,9H), 0.91(t,J = 7.5Hz,3H)
ESI-MS m/z 458 (MH⁺)

[0231]

Example 16(5)

tert-Butyl (2S,4R)-4-(4-amino-6-bromo-5-(((R)-1-phenylethyl)carbamoyl)-7H-pyrrolo [2,3-d]pyrimidin-7-yl)-2-ethylpyrrolidine-1-carboxylate

The compound of Example 16(4) (797 mg), dichlorobis(triphenylphosphine)dipalladium (25 mg), and (R)-(+)-1-phenylethylamine (0.55 mL) were suspended in DMF (8.0 mL), followed by carbon monoxide substitution, and the resultant was then stirred at 80°C for 2 hours. Thereafter, the reaction mixture was cooled to room temperature, water was then added thereto, and the obtained mixture was then extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The

obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain the corresponding amide form. The obtained compound was used in the subsequent reaction without being further purified. The obtained amide form was dissolved in acetonitrile (8.2 mL), and the obtained solution was then cooled to -10°C. Thereafter, N-bromosuccinimide (457 mg) in acetonitrile (8.2 mL) solution was slowly added dropwise to the solution, and the reaction mixture was then stirred for 30 minutes. Thereafter, to the reaction mixture, a sodium sulfite aqueous solution and a sodium hydrogen carbonate aqueous solution were added, and the obtained mixture was then extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain a product of interest (650 mg).

¹HNMR (CDCl₃)δ 8.23(s,1H), 7.49-7.29(m,5H), 6.98(d,J = 7.4Hz,1H), 5.41-5.28(m,1H), 5.24-5.04(m,1H), 4.38-4.22(m,1H), 4.07-3.68(m,1H), 3.19-2.83(m,1H), 2.43-2.29(m,1H), 2.25-1.67(m,3H), 1.66(d,J = 6.9Hz,3H), 1.51(s,9H), 0.98(t,J = 7.4Hz,3H)

ESI-MS m/z 557,559 (MH⁺)

[0232]

Example 16(6)

7-((3R,5S)-1-acryloyl-5-ethylpyrrolidin-3-yl)-4-amino-6-bromo-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

To the compound of Example 16(5) (650 mg), acetonitrile (9.7 mL) was added, and the obtained mixture was then cooled to 0°C. Thereafter, sodium iodide (1.05 g) and trimethylsilyl chloride (0.89 mL) were added, and the obtained mixture was then stirred at 0°C for 1 hour. Thereafter, to the reaction mixture, ethanol (9.7 mL), isopropylethylamine (2.0 mL), and acrylic acid anhydride (0.16 mL) were

successively added, and the obtained mixture was then stirred at 0°C for 30 minutes. Thereafter, to the reaction mixture, ammonia water and water were added, and the obtained mixture was then extracted with ethyl acetate. The gathered organic layer was washed with saturated saline, was then dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : acetone) to obtain a product of interest (256 mg).

¹HNMR (CDCl₃)δ 8.27-8.16(m,1H), 7.47-7.29(m,5H), 6.98(d,J = 7.3Hz,1H), 6.61-6.29(m,2H), 5.84-5.63(m,1H), 5.43-5.26(m,1H), 5.22-5.01(m,1H), 4.80-3.82(m,3H), 3.23-2.92(m,1H), 2.58-2.30(m,1H), 2.22-1.79(m,2H),1.66(d,J = 7.0Hz,3H),1.07-0.96(m,3H)

ESI-MS m/z 511,513 (MH⁺)

[0233]

Example 16(7)

7-((3R,5S)-1-acryloyl-5-ethylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

1.0 M Propyne in DMF solution (0.70 mL) was added to the compound of Example 16(6) (120 mg), acetonitrile (1.2 mL), triethylamine (0.10 mL), PdCl₂(PPh₃)₂ (8.2 mg), and copper(I) iodide (0.4 mg), followed by nitrogen substitution, and the mixture was then stirred at 60°C for 2 hours. Thereafter, the reaction mixture was cooled to room temperature, and ethyl acetate and a saturated ammonium chloride aqueous solution were added to the mixture. The thus obtained mixture was extracted with ethyl acetate, and the gathered organic layer was washed with water, and then with saturated saline. The resultant was dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate : methanol) to obtain a product of interest (102 mg).

¹HNMR (CDCl₃)δ: 8.26(s,1H), 7.79(br d,J = 7.0Hz,1H), 7.46-7.30(m,5H), 6.58-6.31(m,2H), 5.80-5.65(m,1H), 5.33-5.15(m,2H), 4.59-3.85(m,3H), 3.03-2.33(m,2H), 2.25-1.70(m,5H), 1.65(d,J = 6.8Hz,6H), 1.09-0.91(m,3H)

ESI-MS m/z 471 (MH⁺)

[0234]

Example 17

7-((3R,5S)-1-acryloyl-5-ethylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 16, with the exception that cyclopropylacetylene was used instead of 1.0 M propyne in DMF solution in Example 16(7).

¹HNMR (CDCl₃)δ: 8.31-8.16(m,1H), 7.84(d,J = 7.4Hz,1H), 7.46-7.30(m,5H), 6.64-6.32(m,2H), 5.82-5.67(m,1H), 5.39-5.17(m,2H), 4.67-3.81(m,3H), 3.02-2.80(m,1H), 2.62-1.71(m,3H), 1.65(d,J = 6.9Hz,3H), 1.58-1.47(m,1H), 1.06-0.92(m,5H), 0.85-0.70(m,2H)

ESI-MS m/z 497 (MH⁺)

[0235]

Example 18

7-((3R,5R)-1-acryloyl-5-(methoxymethyl)pyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 16, with the exceptions that tert-butyl (2R,4S)-4-hydroxy-2-(methoxymethyl)pyrrolidine-1-carboxylate was used instead of the compound of Example 16(3) in Example 16(4), and that cyclopropylacetylene was used instead of 1.0 M propyne in DMF solution in Example 16(7).

¹HNMR (CDCl₃)δ: 8.29-8.22(m,1H), 7.86-7.80(m,1H), 7.36-7.44(m,4H), 7.34-7.28(m,1H), 6.48-6.37(m,2H), 5.78-5.69(m,1H), 5.29-5.15(m,2H), 4.55-4.30(m,2H), 3.96-3.65(m,3H), 3.42(s,3H), 3.18-3.06(m,0.3H), 2.90-2.80(m,0.3H), 2.64-2.58(m,0.3H), 2.47-2.35(m,0.7H), 1.64(d,3H, J = 6.9Hz), 1.58-1.47(m,1H), 1.04-0.94(m,2H), 0.87-0.69(m,2H)

ESI-MS m/z 513 (MH⁺)

[0236]

Example 19

7-((3R,5R)-1-acryloyl-5-(ethoxymethyl)pyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 16, with the exceptions that tert-butyl (2R,4S)-2-(ethoxymethyl)-4-hydroxypyrrolidine-1-carboxamide was used instead of the compound of Example 16(3) in Example 16(4), and that cyclopropylacetylene was used instead of 1.0 M propyne in DMF solution in Example 16(7).

¹HNMR (CDCl₃)δ: 8.28-8.18(m,1H), 7.84(br d, J = 7.0Hz, 1H), 7.47-7.29(m,5H), 6.82-6.35(m,2H), 5.79-5.68(m,1H), 5.40-5.14(m,2H), 4.63-3.53(m,7H), 3.20-2.79(m,1H), 2.69-2.40(m,1H), 1.67-1.63(m,3H), 1.59-1.47(m,1H), 1.22(t, J = 7.0Hz, 3H), 1.05-0.92(m,2H), 0.87-0.72(m,2H)

ESI-MS m/z 527 (MH⁺)

[0237]

Comparative Example 1

4-Amino-N-(4-(methoxymethyl)phenyl)-7-(1-methylcyclopropyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained by the method described in Example 95 of International Publication No. WO 2017/146116.

ESI-MS m/z 390 (MH⁺)

[0238]

Comparative Example 2

1-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(4-(2-(dimethylamino)-2-oxoethyl)-2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide

The title compound was obtained by the method described in Example 79 of International Publication No. WO 2017/038838.

ESI-MS m/z 505 (MH⁺)

[0239]

Comparative Example 3

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(cyclohexylmethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that cyclohexylmethanamine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (DMSO-d₆)δ: 8.68-8.31(m, 1H) 8.20-8.10(m, 1H) 8.09-7.97(m, 1H) 7.59-7.20(m, 1H) 6.74-6.49(m, 1H) 6.25-6.09(m, 1H) 5.78-5.60(m, 1H) 5.40-5.20(m, 1H) 4.44-4.29(m, 1H) 4.23-3.92(m, 2H) 3.25-3.12(m, 2H) 2.76-2.40(m, 2H) 2.25(s, 3H) 1.81-1.45(m, 5H) 1.43-1.34(m, 3H) 1.30-0.90(m, 6H)

ESI-MS m/z 449 (MH⁺)

[0240]

Comparative Example 4

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-(2-methylbenzyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that o-tolylmethanamine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (DMSO-d₆)δ: 8.37-8.27(m, 1H) 8.19-8.09(m, 1H) 7.39-7.30(m, 1H) 7.26-7.11(m, 4H) 6.68-6.48(m, 1H) 6.24-6.07(m, 1H) 5.80-5.60(m, 1H) 5.36-5.17(m, 1H) 4.52(d, *J* = 5.7 Hz, 2H) 4.42-4.28(m, 1H) 4.22-3.92(m, 2H) 2.73-2.42(m, 2H) 2.33(s, 3H) 2.02(s, 3H) 1.43-1.32(m, 3H)

ESI-MS *m/z* 457 (MH⁺)

[0241]

Comparative Example 5

7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-methyl-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

The title compound was obtained in the same manner as that of Example 1, with the exception that (R)-N-methyl-1-phenylethan-1-amine was used instead of (R)-1-(3,5-difluorophenyl)ethan-1-amine in Example 1(5).

¹HNMR (CDCl₃)δ: 8.23(d, *J* = 5.9 Hz, 1H) 7.50-7.28(m, 4H) 7.09-6.88(m, 1H) 6.57-6.34(m, 2H) 5.79-5.64(m, 1H) 5.22(t, *J* = 9.3 Hz, 1H) 4.48(t, *J* = 9.7 Hz, 0.6H) 4.39-4.20(m, 1.9H) 3.90(t, *J* = 8.6 Hz, 0.5H) 2.85(s, 4H) 2.66-2.63(m, 0.4H) 2.51-2.44(m, 0.6H) 2.07(s, 2H) 1.66(d, *J* = 4.8 Hz, 3H) 1.52(d, *J* = 5.9 Hz, 3H)

ESI-MS *m/z* 471 (MH⁺)

[0242]

Comparative Example 6

Comparative Example 6(1)

tert-Butyl (2S,4R)-4-(4-amino-5-(((R)-1-phenylethyl)carbamoyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylpyrrolidine-1-carboxylate

1.0 M Propyne in DMF solution(2.1 mL) was added to the compound of Example 11(1) (230 mg), acetonitrile (4.6 mL), triethylamine (0.29 mL), PdCl₂(PPh₃)₂ (5.9 mg), and copper(I) iodide (1.6 mg), followed by nitrogen substitution, and the obtained mixture was then stirred at 70°C for 1 hour. Thereafter, the reaction mixture was cooled to room temperature, and ethyl acetate

and a saturated sodium hydrogen carbonate aqueous solution were then added to the mixture. The thus obtained mixture was extracted with ethyl acetate, and the gathered organic layer was washed with water and then with saturated saline. The resultant was dried over anhydrous sodium sulfate, and was then concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane : ethyl acetate) to obtain a product of interest (193 mg).

¹HNMR (CDCl₃)δ: 8.23 (s, 1H) 7.79(d, *J* = 6.8Hz, 1H) 7.46-7.27(m, 5H) 5.40-5.17(m, 2H) 4.28-3.64(m, 3H) 2.85-2.68(m, 1H) 2.46-2.36(m, 1H) 2.15-1.97(m, 3H) 1.62(d, *J* = 6.8Hz, 3H) 1.56-1.32(m, 12H)

ESI-MS *m/z* 503 (MH⁺)

[0243]

Comparative Example 6(2)

4-Amino-7-((3R,5S)-5-methylpyrrolidin-3-yl)-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide hydrochloride

To the compound of Comparative Example 6(1) (530 mg), 4 M hydrochloric acid in 1,4-dioxane solution (5 mL) was added, and the obtained mixture was then stirred at room temperature for 2 hours. Thereafter, the reaction mixture was concentrated under reduced pressure to obtain a product of interest (420 mg).

ESI-MS *m/z* 403 (MH⁺)

[0244]

Comparative Example 6(3)

4-Amino-7-((3R,5S)-1-((E)-but-2-enoyl)-5-methylpyrrolidin-3-yl)-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

To the compound of Comparative Example 6(2) (18 mg), acetonitrile (0.5 mL) was added, and the obtained mixture was then cooled to 0°C. Thereafter, acryloyl chloride (0.004 mL) and diisopropylethylamine (0.036 mL) were added to

the reaction mixture, and the thus obtained mixture was then stirred at 0°C for 1 hour. Thereafter, the reaction mixture was concentrated under reduced pressure, and was then subjected to reverse phase preparative HPLC (water : acetonitrile (0.1% formic acid)) to obtain a product of interest (8.7 mg).

¹HNMR (CDCl₃)δ: 8.31 (s, 1H) 8.14(d,*J* = 6.2Hz, 1H) 7.77(d,*J* = 7.0Hz, 1H) 7.39-7.36(m, 4H) 7.33-7.31(m, 1H) 7.03-6.90(m, 1H) 6.06(dd,*J* = 14.3Hz, 1H) 5.28-5.17(m, 2H) 4.48(t,*J* = 10.1Hz, 1H) 4.35-4.20(m, 2H) 3.88(t, 8.8Hz, 1H) 2.84-2.76(m, 1H) 2.64-2.40(m, 1H) 2.05(d,*J* = 10.6Hz, 3H) 1.92(d,*J* = 6.6Hz, 1H) 1.85(d,*J* = 7.0Hz, 2H) 1.62(d,*J* = 7.0Hz, 3H) 1.55(dd,*J* = 9.0, 5.7Hz, 3H)









ESI-MS *m/z* 471 (MH⁺)

[0245]




The compounds synthesized in the above-described Examples and Comparative Examples are shown below.

[0246]

[Table 1]







Example No.	Structural formula	Example No.	Structural formula
1		2	
3		4	
5		6	
7		8	

9		10	
11		12	
13		14	
15		16	

17		18	
19			

[0247]

[Table 2]

Comparative Example No.	Structural formula	Comparative Example No.	Structural formula
1		2	
3		4	
5		6	

[0248]

Test Example 1 Measurement of phosphorylation activity inhibitory effect (*in vitro*) on wild-type and mutant EGFR

The measurement of the *in vitro* inhibitory activity of a compound against wild-type and mutant EGFR was outsourced to Carna Biosciences, Inc. (Kinase Profiling Book, <https://www.carnabio.com/japanese/product/search.cgi?mode=profiling>).

[0249]

Specifically, first, the compound of the present invention was diluted stepwise with dimethyl sulfoxide (DMSO). Subsequently, the EGFR protein, the substrate peptide (Src tide, final concentration: 1 μ M), magnesium chloride (final concentration: 5 mM), manganese chloride (final concentration: 1 mM), ATP (final concentration: near K_m of each EGFR), and the compound of the present invention in DMSO solution (final concentration of DMSO: 1%) were added to a buffer for the kinase reaction (20 mM HEPES (pH 7.5), 1 mM dithiothreitol, and 0.01% Triton X-100), and the obtained mixture was then incubated at room temperature for 1 hour, so that the kinase reaction was carried out. To the reaction solution, Termination Buffer was added, so as to terminate the kinase reaction. Finally, using LabChip(TM) EZ Reader II (PerkinElmer), an unphosphorylated substrate peptide (S) and a phosphorylated peptide (P) were separated and detected according to microchannel capillary electrophoresis. From the peak heights of S and P, the amount of the phosphorylation reaction was obtained, and the concentration of the compound capable of inhibiting the phosphorylation reaction by 50% was defined as an IC₅₀ value (nM). The results are shown in the following table.

[0250]

[Table 3]

	IC ₅₀ (nmol/L)
kinases	Example compound 11
EGFR	0.47
EGFR [d746-750]	0.25
EGFR [d746-750/T790M]	6.8
EGFR [L858R]	0.36

EGFR [T790M/L858R]	6.6
EGFR [D770_N771insNPG]	0.55

[0251]

From the above results, it was found that the compound of the present invention has excellent inhibitory activity against wild-type and mutant EGFR.

[0252]

Test Example 2 Measurement of growth inhibitory activity against EGFR overexpressing cell line and exon 20 insertion mutant EGFR expressing cell line

Growth inhibitory activity against an EGFR overexpressing cell line and an exon 20 insertion mutant EGFR expressing cell line was evaluated using MCF10A_EGFR cells, MCF10A_EGFR/V769_D770insASV cells, MCF10A_EGFR/D770_N771insSVD cells, and MCF10A_EGFR/H773_V774insNPH cells (Fukushima Medical University) which were cells obtained by introducing the EGFR gene (WT, D769_N770insASV mutant, D770_N771insSVD mutant, H773_V774insNPH mutant) into MDA-MB-468 cells (ATCC) as an EGFR overexpressing human breast cancer cell line, NCI-H1975 cells (ATCC) as L858R and T790M mutant EGFR-positive human lung cancer cells, and MCF10A cells as human normal mammary gland cells.

[0253]

The MDA-MB-468 cells were suspended in Leibovitz's L-15 medium containing 10% inactivated fetal bovine serum. The NCI-H1975 cells were suspended in RPMI-1640 medium containing 10% inactivated fetal bovine serum. The MCF10A_EGFR cells, the MCF10A_EGFR/V769_D770insASV cells, the MCF10A_EGFR/D770_N771insSVD cells, or the MCF10A_EGFR/H773_V774insNPH cells were suspended in DMEM/Ham's F-12 medium (containing L-glutamine, phenol red, HEPES, and sodium pyruvate) containing 10 µg/mL insulin, 500 ng/mL hydrocortisone, 5 µmol/L forskolin, and

5% inactivated horse serum in terms of their final concentrations. Each cell suspension was seeded in each well of a 96-well flat-bottom plate such that the number of cells per well was 500, and was then cultured in a carbon dioxide gas-free culture vessel for the MDA-MB-468 cells and in a 5% carbon dioxide gas-containing culture vessel for the other cells at 37°C for 1 day. The compound of the present invention was prepared at 1 mM in DMSO and then diluted 1/200 with a medium to prepare a 5 μM solution. Thereafter, the compound of the present invention in the DMSO solution was diluted with the medium used in the suspension of the cells, and the obtained solution was then added to each well so that the final concentration of the highest concentration of the test compound was 1000 nM. The obtained mixture was further cultured in a carbon dioxide gas-free culture vessel for the MDA-MB-468 cells and in the 5% carbon dioxide gas-containing culture vessel for the other cells at 37°C for 3 days.

[0254]

The cells at the start of the culture (day 0) and after the culture (day 3) were counted using CellTiter-Glo(R) 2.0 Reagent (Promega Corp.) according to the protocol recommended by the manufacturer. The growth inhibition percentage was calculated according to the equation given below to determine the 50% inhibition concentration (GI50 (nM)) of the test compound. The results are shown in Table 4.

[0255]

1) In the case of $T_{\text{day3}} \geq C_{\text{day0}}$

$$\text{Growth percentage (\%)} = (T_{\text{day3}} - C_{\text{day0}}) / (C_{\text{day3}} - C_{\text{day0}}) \times 100$$

T: Emission intensity from the well to which the test compound was added

C: Emission intensity from the well to which the test compound was not added

day0: Day on which the test compound was added

day3: Evaluation day

[0256]

2) In the case of $T_{\text{day3}} < C_{\text{day0}}$

$$\text{Growth percentage (\%)} = (T_{\text{day3}} - C_{\text{day0}}) / (C_{\text{day0}}) \times 100$$

T: Emission intensity from the well to which the test compound was added

C: Emission intensity from the well to which the test compound was not added

day0: Day on which the test compound was added

day3: Evaluation day

[0257]

[Table 4]

	Cell growth inhibitory activity GI 50 value (nM)					
	MDA-MB-468	NCI-H1975	MCF10A_EGFR cell (EGFR-WT)	MCF10A_EGFR/V769_D770insASV cell	MCF10A_EGFR/D770_N771insSVD cell	MCF10A_EGFR/H773_V774insNPH cell
Example compound 2	81	77	55	6.7	8.2	16
Example compound 11	99	87	81	7.3	10	18
Example compound 12	221	153	206	24	27	50

[0258]

From the above results, it was found that the compound group of the present invention also has excellent cell growth inhibitory activity against the wild-type EGFR overexpressing line MDA-MB-468 cells, the MCF10A_EGFR cells expressing the introduced wild-type EGFR gene, the L858R and T790M mutant EGFR-positive cells NCI-H1975 cells, and the exon 20 insertion mutant EGFR expressing cell lines (MCF10A_EGFR/V769_D770insASV cells, MCF10A_EGFR/D770_N771insSVD cells, and MCF10A_EGFR/H773_V774insNPH cells).

[0259]

Test Example 3 Measurement of growth inhibitory activity against exon 20 insertion mutant EGFR expressing cell line

Growth inhibitory activity against exon 20 insertion mutant EGFR was evaluated using H1975-EGFRinsSVD cells obtained by genetically modifying NCI-H1975 cells so as to express D770_N771insSVD mutant EGFR and to knock out endogenous EGFR (T790M/L858R), and LXF 2478 cells (Charles River Laboratories, Inc.) of V769_D770insASV mutant EGFR-positive human lung cancer patient-derived tumor.

[0260]

The H1975-EGFRinsSVD cells were prepared by introducing PB-CMV-MCS-EF1-RFP+Puro vector encoding D770_N771insSVD (insSVD), together with Super PiggyBacTransposase expression vector, to NCI-H1975 cells by electroporation with Amaxa(R) Cell Line Nucleofector(R) Kit R, then selecting cells using puromycin (Sigma-Aldrich Co. LLC.), then introducing thereto XTN(R) TALENs Site-Specific Nucleases (Transposagen Bio) by electroporation with Amaxa(R) Cell Line Nucleofector(R) Kit R, and selecting, by sequencing, cells in which endogenous EGFR (T790M/L858R) was knocked out.

[0261]

Upon evaluation of cell growth inhibitory effect, the cells of each line were suspended in RPMI-1640 medium. The cell suspension was seeded in each well of a 96-well flat-bottom plate such that the number of cells per well was 3,000, and was then cultured in a 5% carbon dioxide gas-containing culture vessel at 37°C for 1 day. The compound of the present invention or a Comparative Example compound was dissolved at 1 mM in DMSO and then added to each well using Tecan D300e digital dispenser (Tecan Trading AG) such that the final concentration of the highest concentration of the test compound was 1000 nM and the common ratio was 3. The cells were cultured in a 5% carbon dioxide gas-containing culture vessel at 37°C for

3 days. The cells at the start of the culture (day 0) and after the culture (day 3) were counted using CellTiter-Glo(R) 2.0 Reagent (Promega Corp.) according to the protocol recommended by the manufacturer. The growth inhibition percentage was calculated according to the equation given below to determine the 50% inhibition concentration (GI50 (nM)) of the test compound. The results are shown in Table 5.

[0262]

1) In the case of $T_{\text{day3}} \geq C_{\text{day0}}$

$$\text{Growth percentage (\%)} = (T_{\text{day3}} - C_{\text{day0}}) / (C_{\text{day3}} - C_{\text{day0}}) \times 100$$

T: Emission intensity from the well to which the test compound was added

C: Emission intensity from the well to which the test compound was not added

day0: Day on which the test compound was added

day3: Evaluation day

[0263]

2) In the case of $T_{\text{day3}} < C_{\text{day0}}$

$$\text{Growth percentage (\%)} = (T_{\text{day3}} - C_{\text{day0}}) / (C_{\text{day0}}) \times 100$$

T: Emission intensity from the well to which the test compound was added

C: Emission intensity from the well to which the test compound was not added

day0: Day on which the test compound was added

day3: Evaluation day

[0264]

[Table 5]

	Cell growth inhibitory activity GI 50 value (nM)	
	H1975-EGFRinsSVD cell	LXF 2478 cell
Example compound 1	44	29
Example compound 2	9.5	11
Example compound 3	77	24
Example compound 4	13	15
Example compound 5	33	24
Example compound 6	29	29
Example compound 7	33	33
Example compound 8	25	26
Example compound 9	65	34
Example compound 10	39	40
Example compound 11	17	19
Example compound 12	52	48
Example compound 13	48	46
Example compound 14	30	27
Example compound 15	101	58
Comparative Example 1	> 1000	> 1000
Comparative Example 2	> 1000	> 1000

[0265]

From the above results, it was found that the compound group of the present invention also has excellent cell growth inhibitory activity against the exon 20 insertion mutant EGFR expressing cell lines (H1975-EGFRinsSVD and LXF 2478).

[0266]

Test Example 4 Evaluation of oral absorbability

The compound of the present invention was suspended or dissolved in 0.5% HPMC aqueous solution and 0.1 N hydrochloric acid, and the obtained suspension or solution was orally administered to BALB/cA mice (CLEA Japan, Inc.) at a dose of 50 mg/kg/day. At 0.5, 1, 2, 4 and 6 hours after completion of the oral administration, blood was collected from the facial vein over time, so as to obtain plasma. The concentration of the compound in the obtained plasma was measured by LC-MS/MS, and the oral absorbability of the present compound was evaluated.

The results are shown in the following Table 6.

[0267]

[Table 6]

Example No.	AUC 0 - 6 hr ($\mu\text{M}\cdot\text{hr}$)	Example No.	AUC 0 - 6 hr ($\mu\text{M}\cdot\text{hr}$)
1	50	2	15
3	24	4	12
5	20	6	17
7	15	8	15
9	51	10	50
11	31	12	36
13	18	14	27
15	34	16	15
17	21	18	15
19	6.1	Comp. Ex. 2	1.5

[0268]

From the above results, it was found that the compound of the present invention was contained in a sufficient concentration in the plasma, so that the present compound exhibited favorable oral absorbability. In contrast, the compound of Comparative Example 2 had oral absorbability that was more than 4 times more attenuated than the compound of the present invention.

[0269]

Test Example 5 Evaluation of brain penetration properties

The compound of the present invention was suspended or dissolved in 0.5% HPMC aqueous solution and 0.1 N hydrochloric acid, and the obtained suspension or solution was orally administered to BALB/cA mice (CLEA Japan, Inc.) at a dose of 50 mg/kg/day. At 0.5 hours after completion of the oral administration, blood was collected from the facial vein, and whole brain was then excised, so as to obtain plasma and brain samples. Water was added to the obtained brain sample in 3 times the volume of the brain sample, and the resultant was then homogenized using an ultrasonic homogenizer, so as to obtain a brain homogenate. The concentration of the compound in the obtained plasma and brain homogenate was measured by LC-

MS/MS, and the brain penetration properties of the present compound were evaluated from the brain/plasma concentration of the compound.

The results are shown in the following Table 7.

[0270]

[Table 7]

Example No.	Compound concentration in plasma (μ M)	Compound concentration in brain (μ M)	Kp value (Compound concentration in brain/plasma)
1	9.1	1.4	0.15
2	6.6	1.8	0.27
3	11	1.4	0.13
4	8.3	2.8	0.34
5	15	2.2	0.15
6	7.5	1.3	0.17
7	7.9	1.1	0.14
8	9.9	3.3	0.33
9	13	2.4	0.18
10	13	2.4	0.18
11	12	2.7	0.23
12	11	3.2	0.29
13	13	2.8	0.22
14	9.9	2.1	0.21
15	8.1	1.2	0.15
16	12	4.4	0.35
17	17	6.5	0.39
18	7.7	1.6	0.22
19	4.9	0.7	0.14
Comp. Ex. 2	1.6	0.008	0.005

[0271]

From the above results, it was found that the compound of the present invention had a high brain/plasma compound concentration (Kp value) and thus, exhibited favorable brain penetration properties. On the other hand, the brain concentration of the compound of Comparative Example 2 was more than 80 times more attenuated than that of the compound of the present invention.

[0272]

Test Example 6 Antitumor effect confirmation test (*in vivo*) on subcutaneous transplantation models, into which H1975-EGFRinsSVD cell line is transplanted

H1975-EGFRinsSVD cell line was cultured in RPMI-1640 (containing 4.5 g/L glucose, 10 mM HEPES and 1 mM sodium pyruvate) (FUJIFILM Wako Pure Chemical Corporation) medium containing 10% inactivated fetal bovine serum (FBS) in a 5% CO₂ incubator at 37°C.

[0273]

The H1975-EGFRinsSVD cells were resuspended at a concentration of 8×10^7 cells/mL in PBS. The cell suspension was subcutaneously transplanted at 8×10^6 cells/0.1 mL to the right chest of each 6 week old nude mouse (BALB/cAJcl-nu/nu, CLEA Japan, Inc.) using a 1 mL syringe for tuberculin and a 25 G injection needle.

[0274]

When the tumor volumes of nude mice having tumor engraftment became on the order of 100 to 200 mm³, the mice were assigned to groups each involving 6 animals by random stratification such that the average tumor volume was equal among the groups.

[0275]

The test compound used was the compounds of Examples 2, 11, and 12, and a 0.5% HPMC aqueous solution was used as a control. The compounds of Examples 2, 11 and 12 were orally administered at doses of 25 mg/kg/day, 25 mg/kg/day and 50 mg/kg/day, respectively.

[0276]

Each test compound or the control was orally administered every day for 14 days (Days 1 - 14) from the day following the grouping.

[0277]

To compare the transition of tumor growth over time by the administration of each test compound, a tumor volume (which is also referred to as "TV" below) was measured at a frequency of twice a week over time. For the measurement of the body weight, an animal electronic balance was used. A body weight change percentage is also referred to as "BWC" below. A body weight change percentage on the n^{th} day (BWC_n) from the body weight on the n^{th} day (BW_n) was calculated according to the equation given below. The transition of average TV and BWC values of the individuals is shown in Figures 1 and 2.

[0278]

$$\text{BWC}_n (\%) = ((\text{body weight on } n^{\text{th}} \text{ day}) - (\text{body weight on grouping day})) / [(\text{body weight on grouping day}) \times 100]$$

[0279]

When the average TV value of the compound administration group on the final evaluation day (Day 15) was smaller than that of the control group and exhibited statistically significant difference (Dunnett type multiple comparison test), this compound was judged as being effective ($P < 0.001$) and is indicated by the mark * in the drawing. The results are shown in Figure 1.

[0280]

As a result of conducting analysis by the Dunnett type multiple comparison test, it was shown that the tumor volume was statistically significantly low ($P < 0.001$) for all the invention compounds as compared with the control group. From the results of this test, it was found that the compounds of Examples 2, 11, and 12 have excellent antitumor effects against the exon 20 insertion mutant EGFR expressing cell line (H1975-EGFRinsSVD) transplanted into the nude mouse chest. Moreover, a body weight reduction of 20% or more was not observed in all of the mice to which each compound had been administered.

[0281]

Test Example 7 Antitumor effect confirmation test (*in vivo*) on direct brain transplantation models, into which luciferase gene-introduced exon 20 insertion mutant EGFR expressing cell line (H1975-EGFRinsSVD-Luc) is directly transplanted

The antitumor effects and life-extending effects of the invention compound on direct brain transplantation models were evaluated using H1975-EGFRinsSVD-Luc line obtained by introducing luciferase into the human mutant EGFR-introduced cell line H1975-EGFRinsSVD.

[0282]

The H1975-EGFRinsSVD-Luc cells used were prepared by introducing pJTI(R) FAST DEST vector encoding luciferase, together with pJTI(R) PhiC31 Integrase expression vector, to NCI-H1975-EGFRinsSVD cells by electroporation with Amaxa(R) Cell Line Nucleofector(R) Kit R, followed by selection using hygromycin B (Nacalai Tesque, Inc.).

[0283]

The H1975-EGFRinsSVD-Luc cell line was cultured in RPMI-1640 (containing 4.5 g/L glucose, 10 mM HEPES and 1 mM sodium pyruvate) (FUJIFILM Wako Pure Chemical Corporation) medium containing 10% inactivated fetal bovine serum (FBS) in a 5% CO₂ incubator at 37°C.

[0284]

The H1975-EGFRinsSVD-Luc cells were resuspended at a concentration of 12.5×10^7 cells/mL in PBS.

[0285]

Using a mouse ear bar, a nude mouse with 6 to 7 weeks old (BALB/cAJcl-nu/nu, CLEA Japan, Inc.) was fixed in a brain stereotaxic apparatus, and the skin on the top of the head was disinfected by the application of an Isodine-containing

antiseptic solution using a sterile cotton swab and was then excised with a surgical knife.

[0286]

A microdrill was used to drill a hole in the skull, and then, using a needle, a manipulator, and a syringe pump, 2 μ L of the cell suspension was transplanted into the brain at a rate of 0.8 μ L/min.

[0287]

As a reference of the amount of brain tumor, 26 days after the transplantation, Total Flux (Photon/sec) was measured in all of the survival cases, using IVIS (PerkinElmer, Inc., model: Lumina II). Based on the obtained results, 10 animals were assigned to each group by random stratification such that the average total flux was equal among the groups.

[0288]

The test compound used was the compound of Example 11, and a 0.5% HPMC aqueous solution was used as a control. The compound of Example 11 was administered at a dose of 12.5 mg/kg/day or 25 mg/kg/day.

[0289]

The compound of the present invention or the control was orally administered once a day, every day, for 38 days (Days 27 - 64) from the following day of the grouping day.

[0290]

For judgment of the presence or absence of antitumor effects, the value (Log10) obtained by logarithmic transformation of the total flux on the antitumor effect judgment day (Day 47) after 3-week drug administration from the following day (Day 27) of the grouping day was used.

[0291]

A graph was prepared with the value obtained by the average total flux of each group as a vertical axis, and with the number of days (Day) after the transplantation as a horizontal axis. The transition of the total flux over time in the drug administration period was observed.

[0292]

For judgment of the presence or absence of life-extending effects, the number of survival days on the final life-extending effect evaluation day from after cell transplantation (Days 0 - 65) in the test compound group compared with the control group was analyzed by the Log-Rank test.

[0293]

The results are shown in Figures 3 and 4 given below. The value obtained by logarithmic transformation (Log10) of the total flux on Day 47 in each group was analyzed by the Dunnett type multiple comparison test. As a result, it was demonstrated that the aforementioned value of the test compound group was statistically significantly lower than the value of the control group (significance level (both sides): 5%) ($P < 0.001$). From the results of this test, it was found that the compound of the present invention has antitumor effects against the exon 20 insertion mutant EGFR expressing cell line (H1975-EGFRinsSVD-Luc) transplanted into the nude mouse brain.

[0294]

In addition, the number of survival days on the final life-extending effect evaluation day from after cell transplantation (Days 0 - 65) in the test compound group compared with the control group was analyzed by the Log-Rank test. As a result, statistically significant life-extending effects were observed, as compared with the control group ($P < 0.05$).


[0295]

As described above, the compound of the present invention or a salt thereof has EGFR inhibitory activity and has brain penetration properties and as such, is useful as an EGFR inhibitor or a therapeutic agent for EGFR-positive tumor.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

[Claim 1]

A therapeutic agent for the treatment of a disease associated with EGFR, comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 2]

The therapeutic agent according to claim 1, wherein the pyrimidine compound is a compound represented by the following formula (II):



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 3]

The therapeutic agent according to claim 1 or 2, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R_2 is a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups as a substituent(s).

[Claim 4]

The therapeutic agent according to any one of claims 1 to 3, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₃ is a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s).

[Claim 5]

The therapeutic agent according to any one of claims 1 to 4, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₅ is a phenyl group optionally having 1 or 2 substituents selected from the group consisting of fluorine atoms and chlorine atoms.

[Claim 6]

The therapeutic agent according to any one of claims 1 to 5, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₁ is a methyl group, a tert-butyl group, or a cyclopropyl group.

[Claim 7]

The therapeutic agent according to any one of claims 1 to 6, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₂ is a methyl group, an ethyl group, a methoxymethyl group, or an ethoxymethyl group.

[Claim 8]

The therapeutic agent according to any one of claims 1 to 7, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₃ is a methyl group.

[Claim 9]

The therapeutic agent according to any one of claims 1 to 8, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₄ is a hydrogen atom.

[Claim 10]

The therapeutic agent according to any one of claims 1 to 9, wherein the pyrimidine compound is a compound represented by the formula (I) or (II) wherein

R₅ is a phenyl group.

[Claim 11]

The therapeutic agent according to any one of claims 1 to 10, wherein the pyrimidine compound is a compound selected from the following (1) to (3):

(1) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-N-((R)-1-phenylethyl)-6-(prop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide,

(2) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, and

(3) 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(3,3-dimethylbut-1-yn-1-yl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[Claim 12]


The therapeutic agent according to any one of claims 1 to 11, wherein the pyrimidine compound is 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N-((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

[Claim 13]

The therapeutic agent according to any one of claims 1 to 12, wherein the disease associated with EGFR is malignant tumor having EGFR overexpression, EGFR gene amplification, or an EGFR mutation.

[Claim 14]

An EGFR inhibitor comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 15]

A therapeutic agent for the treatment of an EGFR-positive tumor, comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof as an active ingredient:



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 16]

A pharmaceutical composition for the treatment of a disease associated with EGFR, the pharmaceutical composition comprising a pyrimidine compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;

R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and


R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 17]

The pharmaceutical composition according to claim 16, wherein the disease associated with EGFR is malignant tumor having EGFR overexpression, EGFR gene amplification, or an EGFR mutation.

[Claim 18]

A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with EGFR:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 19]

Use of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof in the treatment of a disease associated with EGFR:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 20]

Use of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a therapeutic agent for the treatment of a disease associated with EGFR:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 21]

A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof for the treatment of EGFR-positive tumor:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 22]

Use of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof in the treatment of EGFR-positive tumor:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 23]

Use of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a therapeutic agent for the treatment of EGFR-positive tumor:



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 24]

A method for treatment of a disease associated with EGFR, the method comprising administering an effective amount of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof :



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 25]

A method for treatment of EGFR-positive tumor, the method comprising administering an effective amount of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof :



wherein R₁ represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R₂ represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R₃ represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R₄ represents a hydrogen atom or a C1-C4 alkyl group; and

R₅ represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

[Claim 26]

Use of an effective amount of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof :



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and

R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms,
in the manufacture of a medicament for the treatment of a disease associated with EGFR.

[Claim 27]

Use of an effective amount of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof :



wherein R_1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group;

R_2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group;


R_3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s);

R_4 represents a hydrogen atom or a C1-C4 alkyl group; and


R_5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms,
in the manufacture of a medicament for the treatment of EGFR-positive tumor.

DRAWINGS


[Figure 1]




[Figure 2]



[Figure 3]



[Figure 4]



SEQUENCE LISTING

<110> Taiho Pharmaceutical Co., Ltd.

<120> EGFR Inhibitors

<130> G2643

<150> JP 2020-121525

<151> 2020-07-15

<160> 6

<170> PatentIn version 3.5

<210> 1

<211> 3633

<212> DNA

<213> Homo sapiens

<400> 1

atgcgaccct ccgggacggc cggggcagcg ctcttggcgc tgctggctgc gctctgccc	60
gcgagtcggg ctctggagga aaagaaagt tgccaaggca cgagtaaca gctcacgcag	120
ttgggcactt ttgaagatca ttttctcagc ctccagagga tgttcaataa ctgtgaggtg	180
gtccttggga atttggaat tacctatgtg cagaggaatt atgatctttc cttcttaaag	240
accatccagg aggtggctgg ttatgtcctc attgccctca acacagtgga gcgaattcct	300
ttggaaaacc tgcagatcat cagaggaaat atgtactacg aaaattccta tgccttagca	360
gtcttatcta actatgatgc aaataaaacc ggactgaagg agctgcccac gagaaattta	420
caggaaatcc tgcattggcg cgtgcggttc agcaacaacc ctgccctgtg caacgtggag	480
agcatccagt ggcgggacat agtcagcagt gactttctca gcaacatgtc gatggacttc	540
cagaaccacc tgggcagctg caaaaagtgt gatccaagct gtcccaatgg gagctgctgg	600
ggtgcaggag aggagaactg ccagaaactg accaaaatca tctgtgcca gcagtgctcc	660
gggcgctgcc gtggcaagtc cccagtgac tgctgccaca accagtgtgc tgcaggctgc	720
acaggcccc gggagagcga ctgcctggtc tgccgcaaat tccgagacga agccacgtgc	780
aaggacacct gccccccact catgctctac aacccaccca cgtaccagat ggatgtgaac	840
cccaggggca aatacagctt tggtgccacc tgcgtgaaga agtgtcccc taattatgtg	900
gtgacagatc acggctcgtg cgtccgagcc tgtggggccg acagctatga gatggaggaa	960
gacggcgtcc gcaagtgtaa gaagtgcgaa gggccttgcc gcaaagtgtg taacggaata	1020
ggtattggtg aatttaaaga ctactctcc ataaatgcta cgaatattaa acacttcaaa	1080
aactgcacct ccatcagtgg cgatctccac atcctgccgg tggcatttag gggtgactcc	1140
ttcacacata ctctctctt ggatccacag gaactggata ttctgaaaac cgtaaaggaa	1200
atcacagggt ttttgctgat tcaggcttgg cctgaaaaca ggacggacct ccatgccttt	1260
gagaacctag aaatcatagc cggcaggacc aagcaacatg gtcagttttc tcttgagtc	1320
gtcagcctga acataacatc cttgggatta cgctccctca aggagataag tgatggagat	1380
gtgataattt caggaaacaa aaatttgtgc tatgcaaata caataaactg gaaaaaactg	1440

tttgggacct ccggtcagaa aacccaaaatt ataagcaaca gaggtgaaaa cagctgcaag	1500
gccacaggcc aggtctgcc tgccttgtgc tcccccgagg gctgctgggg cccggagccc	1560
agggactgcg tctcttgccg gaatgtcagc cgaggcaggg aatgcgtgga caagtcaac	1620
cttctggagg gtgagccaag ggagtttgtg gagaactctg agtgcataca gtgccacca	1680
gagtgcctgc ctcaggccat gaacatcacc tgcacaggac ggggaccaga caactgtatc	1740
cagtgtgccc actacattga cggccccac tgcgtcaaga cctgcccggc aggagtcatg	1800
ggagaaaaca acaccctggt ctggaagtac gcagacgccg gccatgtgtg ccacctgtgc	1860
catccaaact gcacctacgg atgcactggg ccaggctctg aaggctgtcc aacgaatggg	1920
cctaagatcc cgtccatcgc cactgggatg gtggggggccc tcctcttgct gctggtggtg	1980
gccctgggga tcggcctctt catgcgaagg cgccacatcg ttcggaagcg cacgctgcgg	2040
aggctgtgc aggagaggga gcttgtggag cctcttacac ccagtggaga agctcccaac	2100
caagctctct tgaggatctt gaaggaaact gaattcaaaa agatcaaagt gctgggctcc	2160
ggtgcgttcg gcacggtgta taagggactc tggatcccag aaggtagaa agttaaatt	2220
cccgctcgta tcaaggaatt aagagaagca acatctccga aagccaaca ggaaatcctc	2280
gatgaagcct acgtgatggc cagcgtggac aacccccacg tgtgccgcct gctgggcatc	2340
tgcctcacct ccaccgtgca gctcatcacg cagctcatgc ctttcggctg cctcctggac	2400
tatgtccggg aacacaaaga caatattggc tcccagtacc tgctcaactg gtgtgtgcag	2460
atcgcaaagg gcatgaacta cttggaggac cgctgccttg tgcaccgca cctggcagcc	2520
aggaacgtac tggtgaaaac accgcagcat gtcaagatca cagatttttg gctggccaaa	2580
ctgctgggtg cggaagagaa agaataccat gcagaaggag gcaaagtgcc tatcaagtgg	2640
atggcattgg aatcaatttt acacagaatc tatacccacc agagtgatgt ctggagctac	2700
ggggtgactg tttgggagtt gatgacctt ggatccaagc catatgacgg aatccctgcc	2760
agcgagatct cctccatcct ggagaaagga gaacgcctcc ctcagccacc catatgtacc	2820
atcgatgtct acatgatcat ggtcaagtgc tggatgatag acgcagatag tcgccccaaag	2880
ttccgtgagt tgatcatcga attctccaaa atggcccagag acccccagcg ctacctgtc	2940
attcaggggg atgaaagaat gcatcttgcca agtcctacag actccaactt ctaccgtgcc	3000
ctgatggatg aagaagacat ggacgacgtg gtggatgccg acgagtacct catcccacag	3060
cagggttct tcagcagccc ctccacgtca cggactcccc tcctgagctc tctgagtga	3120
accagcaaca attccaccgt ggcttgcat gatagaaatg ggctgcaaag ctgtcccatc	3180
aaggaagaca gcttcttgca gcgatacagc tcagaccca caggcgcctt gactgaggac	3240
agcatagacg acaccttcct cccagtgcct gaatacataa accagtccgt tcccaaaagg	3300
cccgctggct ctgtgcagaa tcctgtctat cacaatcagc ctctgaacct cgcgccagc	3360
agagaccac actaccagga cccccacagc actgcagtgg gcaacccga gtatctcaac	3420
actgtccagc ccacctgtgt caacagcaca ttcgacagcc ctgcccactg ggcccagaaa	3480

ggcagccacc aaattagcct ggacaaccct gactaccagc aggacttctt tcccaaggaa 3540
 gccaaagcaa atggcatctt taagggtccc acagctgaaa atgcagaata cctaagggtc 3600
 gcgccacaaa gcagtgaatt tattggagca tga 3633

<210> 2
 <211> 1210
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Arg Pro Ser Gly Thr Ala Gly Ala Ala Leu Leu Ala Leu Leu Ala
 1 5 10 15

Ala Leu Cys Pro Ala Ser Arg Ala Leu Glu Glu Lys Lys Val Cys Gln
 20 25 30

Gly Thr Ser Asn Lys Leu Thr Gln Leu Gly Thr Phe Glu Asp His Phe
 35 40 45

Leu Ser Leu Gln Arg Met Phe Asn Asn Cys Glu Val Val Leu Gly Asn
 50 55 60

Leu Glu Ile Thr Tyr Val Gln Arg Asn Tyr Asp Leu Ser Phe Leu Lys
 65 70 75 80

Thr Ile Gln Glu Val Ala Gly Tyr Val Leu Ile Ala Leu Asn Thr Val
 85 90 95

Glu Arg Ile Pro Leu Glu Asn Leu Gln Ile Ile Arg Gly Asn Met Tyr
 100 105 110

Tyr Glu Asn Ser Tyr Ala Leu Ala Val Leu Ser Asn Tyr Asp Ala Asn
 115 120 125

Lys Thr Gly Leu Lys Glu Leu Pro Met Arg Asn Leu Gln Glu Ile Leu
 130 135 140

His Gly Ala Val Arg Phe Ser Asn Asn Pro Ala Leu Cys Asn Val Glu
 145 150 155 160

Ser Ile Gln Trp Arg Asp Ile Val Ser Ser Asp Phe Leu Ser Asn Met
 165 170 175

Ser Met Asp Phe Gln Asn His Leu Gly Ser Cys Gln Lys Cys Asp Pro
 180 185 190

Ser Cys Pro Asn Gly Ser Cys Trp Gly Ala Gly Glu Glu Asn Cys Gln
 195 200 205

Lys Leu Thr Lys Ile Ile Cys Ala Gln Gln Cys Ser Gly Arg Cys Arg
 210 215 220

Gly Lys Ser Pro Ser Asp Cys Cys His Asn Gln Cys Ala Ala Gly Cys
225 230 235 240

Thr Gly Pro Arg Glu Ser Asp Cys Leu Val Cys Arg Lys Phe Arg Asp
245 250 255

Glu Ala Thr Cys Lys Asp Thr Cys Pro Pro Leu Met Leu Tyr Asn Pro
260 265 270

Thr Thr Tyr Gln Met Asp Val Asn Pro Glu Gly Lys Tyr Ser Phe Gly
275 280 285

Ala Thr Cys Val Lys Lys Cys Pro Arg Asn Tyr Val Val Thr Asp His
290 295 300

Gly Ser Cys Val Arg Ala Cys Gly Ala Asp Ser Tyr Glu Met Glu Glu
305 310 315 320

Asp Gly Val Arg Lys Cys Lys Lys Cys Glu Gly Pro Cys Arg Lys Val
325 330 335

Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp Ser Leu Ser Ile Asn
340 345 350

Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr Ser Ile Ser Gly Asp
355 360 365

Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp Ser Phe Thr His Thr
370 375 380

Pro Pro Leu Asp Pro Gln Glu Leu Asp Ile Leu Lys Thr Val Lys Glu
385 390 395 400

Ile Thr Gly Phe Leu Leu Ile Gln Ala Trp Pro Glu Asn Arg Thr Asp
405 410 415

Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg Gly Arg Thr Lys Gln
420 425 430

His Gly Gln Phe Ser Leu Ala Val Val Ser Leu Asn Ile Thr Ser Leu
435 440 445

Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly Asp Val Ile Ile Ser
450 455 460

Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile Asn Trp Lys Lys Leu
465 470 475 480

Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile Ser Asn Arg Gly Glu
485 490 495

Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His Ala Leu Cys Ser Pro
500 505 510

Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys Val Ser Cys Arg Asn
515 520 525

Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu Leu Glu Gly
530 535 540

Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln Cys His Pro
545 550 555 560

Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly Arg Gly Pro
565 570 575

Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly Pro His Cys Val
580 585 590

Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn Asn Thr Leu Val Trp
595 600 605

Lys Tyr Ala Asp Ala Gly His Val Cys His Leu Cys His Pro Asn Cys
610 615 620

Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly Cys Pro Thr Asn Gly
625 630 635 640

Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val Gly Ala Leu Leu Leu
645 650 655

Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met Arg Arg Arg His
660 665 670

Ile Val Arg Lys Arg Thr Leu Arg Arg Leu Leu Gln Glu Arg Glu Leu
675 680 685

Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro Asn Gln Ala Leu Leu
690 695 700

Arg Ile Leu Lys Glu Thr Glu Phe Lys Lys Ile Lys Val Leu Gly Ser
705 710 715 720

Gly Ala Phe Gly Thr Val Tyr Lys Gly Leu Trp Ile Pro Glu Gly Glu
725 730 735

Lys Val Lys Ile Pro Val Ala Ile Lys Glu Leu Arg Glu Ala Thr Ser
740 745 750

Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Ser
755 760 765

Val Asp Asn Pro His Val Cys Arg Leu Leu Gly Ile Cys Leu Thr Ser

770		775		780
Thr Val Gln Leu Ile Thr Gln Leu Met Pro Phe Gly Cys Leu Leu Asp				
785		790		795 800
Tyr Val Arg Glu His Lys Asp Asn Ile Gly Ser Gln Tyr Leu Leu Asn				
	805		810	815
Trp Cys Val Gln Ile Ala Lys Gly Met Asn Tyr Leu Glu Asp Arg Arg				
	820		825	830
Leu Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Thr Pro				
	835		840	845
Gln His Val Lys Ile Thr Asp Phe Gly Leu Ala Lys Leu Leu Gly Ala				
	850		855	860
Glu Glu Lys Glu Tyr His Ala Glu Gly Gly Lys Val Pro Ile Lys Trp				
865		870	875	880
Met Ala Leu Glu Ser Ile Leu His Arg Ile Tyr Thr His Gln Ser Asp				
	885		890	895
Val Trp Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly Ser				
	900		905	910
Lys Pro Tyr Asp Gly Ile Pro Ala Ser Glu Ile Ser Ser Ile Leu Glu				
	915		920	925
Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr				
	930		935	940
Met Ile Met Val Lys Cys Trp Met Ile Asp Ala Asp Ser Arg Pro Lys				
945		950	955	960
Phe Arg Glu Leu Ile Ile Glu Phe Ser Lys Met Ala Arg Asp Pro Gln				
	965		970	975
Arg Tyr Leu Val Ile Gln Gly Asp Glu Arg Met His Leu Pro Ser Pro				
	980		985	990
Thr Asp Ser Asn Phe Tyr Arg Ala Leu Met Asp Glu Glu Asp Met Asp				
	995		1000	1005
Asp Val Val Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln Gly Phe				
	1010		1015	1020
Phe Ser Ser Pro Ser Thr Ser Arg Thr Pro Leu Leu Ser Ser Leu				
	1025		1030	1035
Ser Ala Thr Ser Asn Asn Ser Thr Val Ala Cys Ile Asp Arg Asn				
	1040		1045	1050

Gly Leu Gln Ser Cys Pro Ile Lys Glu Asp Ser Phe Leu Gln Arg
1055 1060 1065

Tyr Ser Ser Asp Pro Thr Gly Ala Leu Thr Glu Asp Ser Ile Asp
1070 1075 1080

Asp Thr Phe Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val Pro
1085 1090 1095

Lys Arg Pro Ala Gly Ser Val Gln Asn Pro Val Tyr His Asn Gln
1100 1105 1110

Pro Leu Asn Pro Ala Pro Ser Arg Asp Pro His Tyr Gln Asp Pro
1115 1120 1125

His Ser Thr Ala Val Gly Asn Pro Glu Tyr Leu Asn Thr Val Gln
1130 1135 1140

Pro Thr Cys Val Asn Ser Thr Phe Asp Ser Pro Ala His Trp Ala
1145 1150 1155

Gln Lys Gly Ser His Gln Ile Ser Leu Asp Asn Pro Asp Tyr Gln
1160 1165 1170

Gln Asp Phe Phe Pro Lys Glu Ala Lys Pro Asn Gly Ile Phe Lys
1175 1180 1185

Gly Ser Thr Ala Glu Asn Ala Glu Tyr Leu Arg Val Ala Pro Gln
1190 1195 1200

Ser Ser Glu Phe Ile Gly Ala
1205 1210

<210> 3
<211> 3276
<212> DNA
<213> Homo sapiens

<400> 3
atgcgaccct ccgggacggc cggggcagcg ctcttggcgc tgctggctgc gctctgcccg 60
gcgagtcggg ctctggagga aaagaaagtt tgccaaggca cgagtaacaa gctcacgcag 120
ttgggcactt ttgaagatca ttttctcagc ctccagagga tgttcaataa ctgtgaggtg 180
gtccttgga atttggaat tacctatgtg cagaggaatt atgatctttc cttcttaaag 240
accatccagg aggtggctgg ttatgtcctc attgccctca acacagtgga gcgaattcct 300
ttggaaaacc tgcagatcat cagaggaaat atgtactacg aaaattccta tgccttagca 360
gtcttatcta actatgatgc aaataaaacc ggactgaagg agctgcccac gagaaattta 420
cagggccaaa agtgtgatcc aagctgtccc aatgggagct gctgggggtgc aggagaggag 480
aactgccaga aactgaccaa aatcatctgt gccagcagc gtcggggcg ctgccgtggc 540

aagtccccca	gtgactgctg	ccacaaccag	tgtgctgcag	gctgcacagg	ccccgggag	600
agcgactgcc	tggtctgccg	caaattccga	gacgaagcca	cgtagaagga	cacctgcccc	660
ccactcatgc	tctacaaccc	caccacgtac	cagatggatg	tgaaccccga	gggcaaatac	720
agctttggtg	ccacctgcgt	gaagaagtgt	ccccgtaatt	atgtggtgac	agatcacggc	780
tcgtgcgtcc	gagcctgtgg	ggccgacagc	tatgagatgg	aggaagacgg	cgtagcgaag	840
tgtaagaagt	gcgaagggcc	ttgccgcaaa	gtgtgtaacg	gaataggtat	tggtgaattt	900
aaagactcac	tctccataaa	tgctacgaat	attaaacact	tcaaaaactg	cacctccatc	960
agtggcgatc	tccacatcct	gccggtggca	tttaggggtg	actccttcac	acatactcct	1020
cctctggatc	cacaggaact	ggatattctg	aaaaccgtaa	aggaaatcac	agggtttttg	1080
ctgattcagg	cttggcctga	aaacaggacg	gacctccatg	cctttgagaa	cctagaaatc	1140
atacgcgga	ggaccaagca	acatggtcag	ttttctcttg	cagtcgtcag	cctgaacata	1200
acatccttgg	gattacgctc	cctcaaggag	ataagtgatg	gagatgtgat	aatttcagga	1260
aacaaaaatt	tgtgctatgc	aaatacaata	aactggaaaa	aactgtttgg	gacctccggt	1320
cagaaaacca	aaattataag	caacagaggt	gaaaacagct	gcaaggccac	aggccaggtc	1380
tgccatgcct	tgtgctcccc	cgagggtgc	tggggcccg	agcccaggga	ctgctctct	1440
tgccggaatg	tcagccgagg	cagggaatgc	gtggacaagt	gcaaccttct	ggagggtgag	1500
ccaagggagt	ttgtggagaa	ctctgagtgc	atacagtgcc	acccagagtg	cctgcctcag	1560
gccatgaaca	tcacctgcac	aggacgggga	ccagacaact	gtatccagtg	tgcccactac	1620
attgacggcc	cccactgcgt	caagacctgc	ccggcaggag	tcattgggaga	aaacaacacc	1680
ctggtctgga	agtacgcaga	cgccggccat	gtgtgccacc	tgtgccatcc	aaactgcacc	1740
tacggatgca	ctgggccagg	tcttgaaggc	tgtccaacga	atgggcctaa	gatcccgtcc	1800
atcgccactg	ggatgggtggg	ggccctcctc	ttgctgctgg	tggtggccct	ggggatcggc	1860
ctcttcatgc	gaaggcgcca	catcgttcgg	aagcgcacgc	tgccggaggct	gctgcaggag	1920
agggagcttg	tggagcctct	tacaccaggt	ggagaagctc	ccaaccaagc	tctcttgagg	1980
atcttgaagg	aaactgaatt	caaaaagatc	aaagtgtggg	gctccggtgc	gttcggcacg	2040
gtgtataagg	gactctggat	cccagaagggt	gagaaagtta	aaattcccgt	cgctatcaag	2100
gaattaagag	aagcaacatc	tccgaaagcc	aacaaggaaa	tcctcgatga	agcctacgtg	2160
atggccagcg	tggacaaccc	ccacgtgtgc	cgctgctggg	gcatctgcct	cacctccacc	2220
gtgcagctca	tcacgcagct	catgcccttc	ggctgcctcc	tggaactatgt	ccgggaacac	2280
aaagacaata	ttggctccca	gtacctgctc	aactgggtgtg	tgacagatcg	aaagggcag	2340
aactacttgg	aggaccgtcg	cttgggtgcac	cgcgacctgg	cagccaggaa	cgtactgggtg	2400
aaaacaccgc	agcatgtcaa	gatcacagat	tttgggctgg	ccaaactgct	gggtgcggaa	2460
gagaaagaat	accatgcaga	aggaggcaaa	gtgcctatca	agtggatggc	attggaatca	2520
attttacaca	gaatctatac	ccaccagagt	gatgtctgga	gctacggggg	gactgtttgg	2580

gagttgatga cctttggatc caagccatat gacggaatcc ctgccagcga gatctcctcc 2640
atcctggaga aaggagaacg cctccctcag ccacccatat gtaccatcga tgtctacatg 2700
atcatggtca agtgctggat gatagacgca gatagtcgcc caaagttccg tgagttgatc 2760
atcgaattct ccaaaatggc ccgagacccc cagcgctacc ttgtcattca gggggatgaa 2820
agaatgcatt tgccaagtcc tacagactcc aacttctacc gtgccctgat ggatgaagaa 2880
gacatggacg acgtgggtga tgccgacgag tacctcatcc cacagcaggg cttcttcagc 2940
agcccccca cgtcacggac tccccctctg agctctctga gtgcaaccag caacaattcc 3000
accgtggctt gcattgatag aaatgggctg caaagctgtc ccatcaagga agacagcttc 3060
ttgcagcgat acagctcaga cccacagggc gccttgactg aggacagcat agacgacacc 3120
ttcctcccag tgcttggtga gtggcttgtc tggaacagc cctgctcctc aacctcctcg 3180
accactcag cagcagccag tctccagtgt ccaagccagg tgctccctcc agcatctcca 3240
gagggggaaa cagtggcaga tttgcagaca cagtga 3276

<210> 4
<211> 1091
<212> PRT
<213> Homo sapiens

<400> 4

Met Arg Pro Ser Gly Thr Ala Gly Ala Ala Leu Leu Ala Leu Leu Ala
1 5 10 15

Ala Leu Cys Pro Ala Ser Arg Ala Leu Glu Glu Lys Lys Val Cys Gln
20 25 30

Gly Thr Ser Asn Lys Leu Thr Gln Leu Gly Thr Phe Glu Asp His Phe
35 40 45

Leu Ser Leu Gln Arg Met Phe Asn Asn Cys Glu Val Val Leu Gly Asn
50 55 60

Leu Glu Ile Thr Tyr Val Gln Arg Asn Tyr Asp Leu Ser Phe Leu Lys
65 70 75 80

Thr Ile Gln Glu Val Ala Gly Tyr Val Leu Ile Ala Leu Asn Thr Val
85 90 95

Glu Arg Ile Pro Leu Glu Asn Leu Gln Ile Ile Arg Gly Asn Met Tyr
100 105 110

Tyr Glu Asn Ser Tyr Ala Leu Ala Val Leu Ser Asn Tyr Asp Ala Asn
115 120 125

Lys Thr Gly Leu Lys Glu Leu Pro Met Arg Asn Leu Gln Gly Gln Lys
130 135 140

Cys Asp Pro Ser Cys Pro Asn Gly Ser Cys Trp Gly Ala Gly Glu Glu

145		150		155		160
Asn Cys Gln Lys	Leu Thr Lys Ile Ile	Cys Ala Gln Gln Cys Ser Gly				
	165	170			175	
Arg Cys Arg Gly	Lys Ser Pro Ser Asp	Cys Cys His Asn Gln Cys Ala				
	180	185			190	
Ala Gly Cys Thr	Gly Pro Arg Glu Ser Asp	Cys Leu Val Cys Arg Lys				
	195	200			205	
Phe Arg Asp Glu	Ala Thr Cys Lys Asp Thr	Cys Pro Pro Leu Met Leu				
	210	215			220	
Tyr Asn Pro Thr	Thr Tyr Gln Met Asp Val	Asn Pro Glu Gly Lys Tyr				
	225	230			235	
Ser Phe Gly Ala	Thr Cys Val Lys Lys Cys	Pro Arg Asn Tyr Val Val				
	245	250			255	
Thr Asp His Gly	Ser Cys Val Arg Ala Cys	Gly Ala Asp Ser Tyr Glu				
	260	265			270	
Met Glu Glu Asp	Gly Val Arg Lys Cys Lys	Lys Cys Glu Gly Pro Cys				
	275	280			285	
Arg Lys Val Cys	Asn Gly Ile Gly Ile Gly	Glu Phe Lys Asp Ser Leu				
	290	295			300	
Ser Ile Asn Ala	Thr Asn Ile Lys His Phe	Lys Asn Cys Thr Ser Ile				
	305	310			315	
Ser Gly Asp Leu	His Ile Leu Pro Val Ala	Phe Arg Gly Asp Ser Phe				
	325	330			335	
Thr His Thr Pro	Pro Leu Asp Pro Gln Glu	Leu Asp Ile Leu Lys Thr				
	340	345			350	
Val Lys Glu Ile	Thr Gly Phe Leu Leu Ile	Gln Ala Trp Pro Glu Asn				
	355	360			365	
Arg Thr Asp Leu	His Ala Phe Glu Asn Leu	Glu Ile Ile Arg Gly Arg				
	370	375			380	
Thr Lys Gln His	Gly Gln Phe Ser Leu Ala	Val Val Ser Leu Asn Ile				
	385	390			395	
Thr Ser Leu Gly	Leu Arg Ser Leu Lys Glu	Ile Ser Asp Gly Asp Val				
	405	410			415	
Ile Ile Ser Gly	Asn Lys Asn Leu Cys Tyr	Ala Asn Thr Ile Asn Trp				
	420	425			430	

Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile Ser Asn
435 440 445

Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His Ala Leu
450 455 460

Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys Val Ser
465 470 475 480

Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu
485 490 495

Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln
500 505 510

Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly
515 520 525

Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly Pro
530 535 540

His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn Asn Thr
545 550 555 560

Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys His Leu Cys His
565 570 575

Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly Cys Pro
580 585 590

Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val Gly Ala
595 600 605

Leu Leu Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met Arg
610 615 620

Arg Arg His Ile Val Arg Lys Arg Thr Leu Arg Arg Leu Leu Gln Glu
625 630 635 640

Arg Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro Asn Gln
645 650 655

Ala Leu Leu Arg Ile Leu Lys Glu Thr Glu Phe Lys Lys Ile Lys Val
660 665 670

Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys Gly Leu Trp Ile Pro
675 680 685

Glu Gly Glu Lys Val Lys Ile Pro Val Ala Ile Lys Glu Leu Arg Glu
690 695 700

Ala Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val
705 710 715 720

Met Ala Ser Val Asp Asn Pro His Val Cys Arg Leu Leu Gly Ile Cys
725 730 735

Leu Thr Ser Thr Val Gln Leu Ile Thr Gln Leu Met Pro Phe Gly Cys
740 745 750

Leu Leu Asp Tyr Val Arg Glu His Lys Asp Asn Ile Gly Ser Gln Tyr
755 760 765

Leu Leu Asn Trp Cys Val Gln Ile Ala Lys Gly Met Asn Tyr Leu Glu
770 775 780

Asp Arg Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val
785 790 795 800

Lys Thr Pro Gln His Val Lys Ile Thr Asp Phe Gly Leu Ala Lys Leu
805 810 815

Leu Gly Ala Glu Glu Lys Glu Tyr His Ala Glu Gly Gly Lys Val Pro
820 825 830

Ile Lys Trp Met Ala Leu Glu Ser Ile Leu His Arg Ile Tyr Thr His
835 840 845

Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr
850 855 860

Phe Gly Ser Lys Pro Tyr Asp Gly Ile Pro Ala Ser Glu Ile Ser Ser
865 870 875 880

Ile Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile
885 890 895

Asp Val Tyr Met Ile Met Val Lys Cys Trp Met Ile Asp Ala Asp Ser
900 905 910

Arg Pro Lys Phe Arg Glu Leu Ile Ile Glu Phe Ser Lys Met Ala Arg
915 920 925

Asp Pro Gln Arg Tyr Leu Val Ile Gln Gly Asp Glu Arg Met His Leu
930 935 940

Pro Ser Pro Thr Asp Ser Asn Phe Tyr Arg Ala Leu Met Asp Glu Glu
945 950 955 960

Asp Met Asp Asp Val Val Asp Ala Asp Glu Tyr Leu Ile Pro Gln Gln
965 970 975

Gly Phe Phe Ser Ser Pro Ser Thr Ser Arg Thr Pro Leu Leu Ser Ser
980 985 990

Leu Ser Ala Thr Ser Asn Asn Ser Thr Val Ala Cys Ile Asp Arg Asn
995 1000 1005

Gly Leu Gln Ser Cys Pro Ile Lys Glu Asp Ser Phe Leu Gln Arg
1010 1015 1020

Tyr Ser Ser Asp Pro Thr Gly Ala Leu Thr Glu Asp Ser Ile Asp
1025 1030 1035

Asp Thr Phe Leu Pro Val Pro Gly Glu Trp Leu Val Trp Lys Gln
1040 1045 1050

Ser Cys Ser Ser Thr Ser Ser Thr His Ser Ala Ala Ala Ser Leu
1055 1060 1065

Gln Cys Pro Ser Gln Val Leu Pro Pro Ala Ser Pro Glu Gly Glu
1070 1075 1080

Thr Val Ala Asp Leu Gln Thr Gln
1085 1090

<210> 5
<211> 2832
<212> DNA
<213> Homo sapiens

<400> 5
atgcgaccct ccgggacggc cggggcagcg ctcttggcgc tgctggctgc gctctgcccg 60
gcgagtcggg ctctggagga aaagaaaggt aattatgtgg tgacagatca cggctcgtgc 120
gtccgagcct gtggggccga cagctatgag atggaggaag acggcgtccg caagtgtgaa 180
aagtgcgaag ggcccttgccg caaagtgtgt aacggaatag gtattggtga atttaaagac 240
tcactctcca taaatgctac gaatattaaa cacttcaaaa actgcacctc catcagtggc 300
gatctccaca tcctgccggt ggcathtagg ggtgactcct tcacacatac tcctcctctg 360
gatccacagg aactggatat tctgaaaacc gtaaaggaaa tcacagggtt ttgctgatt 420
caggcttggc ctgaaaacag gacggacctc catgcctttg agaacctaga aatcatacgc 480
ggcaggacca agcaacatgg tcagttttct cttgcagtcg tcagcctgaa cataacatcc 540
ttgggattac gctccctcaa ggagataagt gatggagatg tgataatttc aggaacaaaa 600
aatttgctgt atgcaaatac aataaactgg aaaaaactgt ttgggacctc cggtcagaaa 660
acaaaaatta taagcaacag aggtgaaaac agctgcaagg ccacaggcca ggtctgcat 720
gccttgctgt ccccgaggg ctgctggggc ccggagccca gggactgcgt ctcttgccgg 780
aatgtcagcc gaggcaggga atgcgtggac aagtgaacc ttctggaggg tgagccaagg 840
gagtttgtgg agaactctga gtgcatacag tgccaccag agtgcctgcc tcaggccatg 900
aacatcacct gcacaggacg gggaccagac aactgtatcc agtgtgccca ctacattgac 960

ggccccact gcgtcaagac ctgcccggca ggagtcattg gagaaaacaa caccctggtc	1020
tggaagtacg cagacgccgg ccatgtgtgc cacctgtgcc atccaaactg cacctacgga	1080
tgactgggc caggtcttga aggctgtcca acgaatgggc ctaagatccc gtccatcgcc	1140
actgggatgg tgggggccct cctcttgctg ctgggtggtg ccctggggat cggcctcttc	1200
atgcgaaggc gccacatcgt tcggaagcgc acgctgcgga ggctgctgca ggagaggag	1260
cttgtggagc ctcttacacc cagtggagaa gctcccaacc aagctctctt gaggatcttg	1320
aaggaaactg aattcaaaaa gatcaaagtg ctgggctccg gtgcgttcgg cacggtgtat	1380
aagggactct ggatcccaga aggtgagaaa gttaaaattc ccgtcgctat caaggaatta	1440
agagaagcaa catctccgaa agccaacaag gaaatcctcg atgaagccta cgtgatggcc	1500
agcgtggaca acccccacgt gtgccgcctg ctgggcatct gcctcacctc caccgtgcag	1560
ctcatcacgc agctcatgcc ctctggctgc ctcttgact atgtccggga acacaaagac	1620
aatattggct ccagctacgt gctcaactgg tgtgtgcaga tcgcaaagg catgaactac	1680
ttggaggacc gtcgcttggt gcaccgcgac ctggcagcca ggaacgtact ggtgaaaaca	1740
ccgcagcatg tcaagatcac agatcttggg ctggccaaac tgctgggtgc ggaagagaaa	1800
gaataccatg cagaaggagg caaagtgcct atcaagtgga tggcattgga atcaatttta	1860
cacagaatct ataccacca gaggatgtc tggagctacg gggtgactgt ttgggagttg	1920
atgacctttg gatccaagcc atatgacgga atccctgcc gcgagatctc ctccatcctg	1980
gagaaaggag aacgcctccc tcagccaccc atatgtacca tcgatgtcta catgatcatg	2040
gtcaagtgtt ggatgataga cgcagatagt cgcccaaagt tccgtgagtt gatcatcgaa	2100
ttctccaaaa tggcccgaga ccccgagcgc taccttgctc ttccaggggga tgaaagaatg	2160
catttgccaa gtcctacaga ctccaacttc taccgtgccc tgatggatga agaagacatg	2220
gacgacgtgg tggatgccga cgagtacctc atccacagc agggcttctt cagcagcccc	2280
tccacgtcac ggactcccct cctgagctct ctgagtgcaa ccagcaacaa ttccaccgtg	2340
gcttgcatg atagaaatgg gctgcaaagc tgtcccatca aggaagacag cttcttgag	2400
cgatacagct cagacccac aggcgccttg actgaggaca gcatagacga caccttcctc	2460
ccagtgcctg aatacataaa ccagtcctgt cccaaaaggc ccgctggctc tgtgcagaat	2520
cctgtctatc acaatcagcc tctgaacccc gcgcccagca gagaccaca ctaccaggac	2580
ccccacagca ctgcagtggg caaccccgag tatctcaaca ctgtccagcc cacctgtgtc	2640
aacagcacat tcgacagccc tgcccactgg gccagaaag gcagccacca aattagcctg	2700
gacaaccctg actaccagca ggacttcttt cccaaggaag ccaagccaaa tggcatcttt	2760
aagggtcca cagctgaaaa tgcagaatac ctaagggtcg cgccacaaag cagtgaattt	2820
attggagcat ga	2832

<213> Homo sapiens

<400> 6

Met Arg Pro Ser Gly Thr Ala Gly Ala Ala Leu Leu Ala Leu Leu Ala
1 5 10 15

Ala Leu Cys Pro Ala Ser Arg Ala Leu Glu Glu Lys Lys Gly Asn Tyr
20 25 30

Val Val Thr Asp His Gly Ser Cys Val Arg Ala Cys Gly Ala Asp Ser
35 40 45

Tyr Glu Met Glu Glu Asp Gly Val Arg Lys Cys Lys Lys Cys Glu Gly
50 55 60

Pro Cys Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp
65 70 75 80

Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr
85 90 95

Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp
100 105 110

Ser Phe Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp Ile Leu
115 120 125

Lys Thr Val Lys Glu Ile Thr Gly Phe Leu Leu Ile Gln Ala Trp Pro
130 135 140

Glu Asn Arg Thr Asp Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg
145 150 155 160

Gly Arg Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val Val Ser Leu
165 170 175

Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly
180 185 190

Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile
195 200 205

Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile
210 215 220

Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His
225 230 235 240

Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys
245 250 255

Val Ser Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys

260

265

270

Asn Leu Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys
 275 280 285

Ile Gln Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys
 290 295 300

Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp
 305 310 315 320

Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn
 325 330 335

Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys His Leu
 340 345 350

Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly
 355 360 365

Cys Pro Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val
 370 375 380

Gly Ala Leu Leu Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe
 385 390 395 400

Met Arg Arg Arg His Ile Val Arg Lys Arg Thr Leu Arg Arg Leu Leu
 405 410 415

Gln Glu Arg Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro
 420 425 430

Asn Gln Ala Leu Leu Arg Ile Leu Lys Glu Thr Glu Phe Lys Lys Ile
 435 440 445

Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys Gly Leu Trp
 450 455 460

Ile Pro Glu Gly Glu Lys Val Lys Ile Pro Val Ala Ile Lys Glu Leu
 465 470 475 480

Arg Glu Ala Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala
 485 490 495

Tyr Val Met Ala Ser Val Asp Asn Pro His Val Cys Arg Leu Leu Gly
 500 505 510

Ile Cys Leu Thr Ser Thr Val Gln Leu Ile Thr Gln Leu Met Pro Phe
 515 520 525

Gly Cys Leu Leu Asp Tyr Val Arg Glu His Lys Asp Asn Ile Gly Ser
 530 535 540

Gln Tyr Leu Leu Asn Trp Cys Val Gln Ile Ala Lys Gly Met Asn Tyr
545 550 555 560

Leu Glu Asp Arg Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn Val
565 570 575

Leu Val Lys Thr Pro Gln His Val Lys Ile Thr Asp Phe Gly Leu Ala
580 585 590

Lys Leu Leu Gly Ala Glu Glu Lys Glu Tyr His Ala Glu Gly Gly Lys
595 600 605

Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu His Arg Ile Tyr
610 615 620

Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val Trp Glu Leu
625 630 635 640

Met Thr Phe Gly Ser Lys Pro Tyr Asp Gly Ile Pro Ala Ser Glu Ile
645 650 655

Ser Ser Ile Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys
660 665 670

Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met Ile Asp Ala
675 680 685

Asp Ser Arg Pro Lys Phe Arg Glu Leu Ile Ile Glu Phe Ser Lys Met
690 695 700

Ala Arg Asp Pro Gln Arg Tyr Leu Val Ile Gln Gly Asp Glu Arg Met
705 710 715 720

His Leu Pro Ser Pro Thr Asp Ser Asn Phe Tyr Arg Ala Leu Met Asp
725 730 735

Glu Glu Asp Met Asp Asp Val Val Asp Ala Asp Glu Tyr Leu Ile Pro
740 745 750

Gln Gln Gly Phe Phe Ser Ser Pro Ser Thr Ser Arg Thr Pro Leu Leu
755 760 765

Ser Ser Leu Ser Ala Thr Ser Asn Asn Ser Thr Val Ala Cys Ile Asp
770 775 780

Arg Asn Gly Leu Gln Ser Cys Pro Ile Lys Glu Asp Ser Phe Leu Gln
785 790 795 800

Arg Tyr Ser Ser Asp Pro Thr Gly Ala Leu Thr Glu Asp Ser Ile Asp
805 810 815

Asp Thr Phe Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val Pro Lys
820 825 830

Arg Pro Ala Gly Ser Val Gln Asn Pro Val Tyr His Asn Gln Pro Leu
835 840 845

Asn Pro Ala Pro Ser Arg Asp Pro His Tyr Gln Asp Pro His Ser Thr
850 855 860

Ala Val Gly Asn Pro Glu Tyr Leu Asn Thr Val Gln Pro Thr Cys Val
865 870 875 880

Asn Ser Thr Phe Asp Ser Pro Ala His Trp Ala Gln Lys Gly Ser His
885 890 895

Gln Ile Ser Leu Asp Asn Pro Asp Tyr Gln Gln Asp Phe Phe Pro Lys
900 905 910

Glu Ala Lys Pro Asn Gly Ile Phe Lys Gly Ser Thr Ala Glu Asn Ala
915 920 925

Glu Tyr Leu Arg Val Ala Pro Gln Ser Ser Glu Phe Ile Gly Ala
930 935 940